Published in final edited form as:

Microbiol Spectr. 2017 August ; 5(4): . doi:10.1128/microbiolspec.BAD-0006-2016.

Ecological therapeutic opportunities for oral diseases

Anilei Hoare¹, Philip D. Marsh², and Patricia I. Diaz¹

¹Division of Periodontology, Department of Oral Health and Diagnostic Sciences, UConn Health, Farmington, CT, USA

²Division of Oral Biology, School of Dentistry, University of Leeds, Leeds, UK

SUMMARY

The three main oral diseases of humans, that is caries, periodontal diseases and oral candidiasis, are associated with microbiome shifts initiated by changes in the oral environment and/or decreased effectiveness of mucosal immune surveillance. In this review we discuss the role that microbial-based therapies may have in the control of these conditions. Most investigations on the use of microorganisms for management of oral disease have been conducted with probiotic strains with some positive but very discrete clinical outcomes. Other strategies such as whole oral microbiome transplantation or modification of community function by enrichment with health-promoting indigenous oral strains may offer more promise but research in this field is still in its infancy. Any microbial-based therapeutics for oral conditions, however, are likely to be only one component within a holistic preventive strategy that should also aim at modification of the environmental influences responsible for the initiation and perpetuation of microbiome shifts associated with oral dysbiosis.

INTRODUCTION

The oral microbiome is formed by hundreds of microbial species, including bacteria, fungi, archaea and viruses, which coexist in specific and organized arrangements in the different habitats of the oral cavity (1, 2, 3, 4, 5, 6, 7, 8). Oral sub-habitats include the mucosa, covered by keratinized and non-keratinized stratified squamous epithelium, the papillary surface of the tongue dorsum and the hard structures of teeth, which are comprised by those above (supragingival) and below (subgingival) the gingival margin. The distinct environmental characteristics found in each of these habitats promote the development of unique microbial communities that, although living in close proximity, can be clearly discriminated from each other (9, 10, 11, 12). Moreover, the microbial composition of these communities is critical to oral health with the main oral diseases characterized by deleterious alterations in microbiome community structure at specific sub-habitats (13, 14).

As in other human mucosal compartments, an understanding of the composition of health and disease-associated communities, together with the development of treatments to attempt the restoration of healthy communities in diseased individuals, has been the subject of increasing research. In this review, we present an overview of the main oral diseases and a critical evaluation of potential microbial-based therapies. We conclude with a perspective on what we believe are key points regarding the etiology of oral diseases that need to be taken into account when developing microbial-based therapeutics for oral conditions.

1. Ecological factors mediating the assembly of oral communities

The oral cavity sub-habitats are colonized by uniquely adapted microbial communities. As other accessible surfaces of the human body, like skin, upper respiratory tract, gastrointestinal tract and vagina, the oral cavity is colonized soon after birth (15). The oral microbiome is one of the most complex and diverse microbial communities, harboring hundreds of species (2, 16). The distribution of such species within oral sub-habitats is determined by a number of factors such as: (i) the characteristics of the surfaces available for attachment, (ii) oxygen availability, (iii) exposure to nutrients from the diet of the host, and (iv) exposure to host products delivered by saliva and gingival crevicular fluid. Microbial successions and inter-species interactions also shape the development of oral communities.

Two different types of surfaces, hard and soft, are available for colonization in the oral cavity. The presence of hard, non-shedding surfaces is a unique feature of the mouth as tooth surfaces (and dentures) allow the development of permanent communities and substantial biomass unless disrupted by regular oral hygiene; in contrast, soft mucosal surfaces promote constant community turnover due to epithelial cell shedding. Both types of surfaces are constantly bathed by saliva, with salivary glycoproteins and proteins adsorbing in a selective way to create a conditioning film. The glycoproteins and proteins in the conditioning film serve as ligands attracting specific species from the genera *Streptococcus*, *Actinomyces*, *Capnocytophaga*, *Eikenella*, *Haemophilus*, *Prevotella*, *Propionibacterium* and *Veillonella*, among others, which are considered early colonizers (17, 18). These microorganisms possess specific arrangements of surface ligands (usually proteins) that allow their adherence (19). Species such as *Streptococcus mitis* and *Streptococcus sanguinis* recognize sialic-acid residues present in adsorbed salivary mucins (20, 21, 22, 23). Other species, such as *Actinomyces* spp. produce enzymes that actively modify adsorbed glycoproteins exposing specific saccharide residues (cryptic receptors), which mediate their own attachment (24, 25). Additionally, most of the indigenous streptococci express polypeptides of the AgI/II family that mediate the recognition of salivary glycoproteins such as gp-340 and their adhesion to epithelial cells (26, 27, 28). This group of peptides is also involved in streptococcal attachment to extracellular matrix components such as fibronectin, collagen and laminin (29, 30), which are exposed when epithelial integrity is disrupted. Thus, selective recognition by early colonizers of molecules exposed at the different surfaces determines and confers specificity to early microbial colonization events.

The attachment of early colonizers to tooth surfaces provides new ligands for the colonization of other species that successively adhere giving place to the formation of a biofilm (31). Interspecies communication and microbial succession also constitute important aspects of community assembly at different oral surfaces. Classic studies on the physical interactions (coaggregation and coadhesion) among oral species have demonstrated that bacterial/bacterial and fungal/bacterial cell recognition and attachment are highly specific (32, 33, 34, 35, 36). Indeed, analysis of dental plaque shows that oral microbial assemblages are specifically organized structures in which individual taxa are arranged in a way suggestive of their functional niche in the consortium (6, 8, 37, 38). For example, in a 9-taxa consortium recently identified in supragingival plaque, filamentous corynebacteria occupied the central position with other taxa radially arranged around them. Anaerobic taxa tended to

be in the interior, whereas facultative or obligate aerobes were located at the periphery of the consortium. Consumers and producers of certain metabolites, such as lactate, tended to be near each other (6). Such highly organized spatial arrangements are likely to result from and facilitate a great variety of inter-species interactions, including the formation of metabolic networks (17).

Interactions among neighboring microbial species in oral communities could be synergistic or antagonistic in nature. One example of synergism in the oral cavity is the collective degradation of salivary glycoproteins by microbial consortia, in which complementary enzymatic activities allow the utilization of mucins in saliva as energy source, as no microorganism possesses the diverse array of enzymes needed for their complete breakdown (39). Also, several examples of food chains in which a metabolic product of one species is utilized as primary energy source by a partner species have been documented (40, 41, 42). Antagonistic interactions mediated by the production of bacteriocins and hydrogen peroxide may also affect community assembly (43, 44, 45, 46, 47, 48).

The interaction of communities with the host also plays a key role in community development. Multiple factors found in the mucosa, saliva and gingival crevicular fluid (GCF), a serum-like exudate constantly flowing between the gingiva and teeth, modulate the growth of the resident microbiota at the different surfaces (49, 50, 51, 52). Antimicrobial peptides of the β -defensin family (hBDs) are found in various locations of the oral cavity such as oral mucosa, gingiva, tongue epithelium, and salivary glands (53). These peptides are believed to selectively control the growth of resident microorganisms (49). In saliva, multiple antimicrobial activities have been described such as the inhibitory effect of histatins against *Candida* and *Streptococcus*; the antimicrobial activity of cystatins on *Porphyromonas gingivalis*, and cathelicidin LL-37 activity against *Candida* spp. (54, 55, 56, 57). Other molecules such as lactoferrin, lysozyme, and a variety of antimicrobial peptides present in saliva may also influence the composition of the microbial community (for a review see Marsh et al. (52)). Finally, elements of the complement system found in GCF may modulate colonization of the subgingival sulcus (50, 58).

Depending of the location in the oral cavity, the sources of nutrients for microorganisms also differ. In exposed surfaces such as tongue, mucosa and supragingival surfaces of teeth, dietary products as well as saliva components are the main available nutritional sources, while in the subgingival crevice the resident microorganisms obtain nutrients mainly from GCF. Saliva contains glycoproteins such as mucins, amylase, and immunoglobulin (Ig) A (52, 59), while GCF contains many serum-derived proteins, such as hemoglobin-derived peptides, IgM, IgG and albumin, which serve as nutrients for sub-gingival species (50, 60, 61, 62). Bacteria from supragingival plaque use host glycoproteins as a major energy source and function as a microbial community to sequentially degrade these structurally complex molecules (39, 63). Enrichment cultivation studies in serum and evaluation of the growth of bacteria in the presence of serum proteins suggest that the protein and iron-rich GCF promotes the growth of Gram-negative anaerobic proteolytic taxa, which characterize subgingival plaque (61, 64, 65, 66). In contrast, dietary carbohydrates mostly affect the community structure of supragingival plaque with their frequent intake promoting an

enrichment of species with an efficient carbohydrate metabolism and an ability to grow well at acidic pH values (67, 68).

Oxygen availability is another important factor driving the selective colonization of microbes in the oral cavity, since it varies widely among the different surfaces found in the mouth. The gingival crevice constitutes a highly reduced area with E_h levels as low as -300 mV as a consequence of low tension of oxygen (69, 70, 71). Therefore, this environment selects mostly obligately anaerobic species, while supragingival plaque is enriched with aerobic and facultative microorganisms. Anaerobic bacteria also are found in greater proportions in the tongue crypts, which serve as an anaerobic “pocket-like” reservoir for microbes (72).

2. Ecological aspects of oral disease etiology

The three main oral diseases, that is caries, periodontal diseases and oral candidiasis, are associated with dysbiosis of the resident oral microbiome. In the three conditions there is an overgrowth of certain indigenous microorganisms, which become the dominant species at the affected site at the expense of health-associated taxa. Figure 1 summarizes the factors mediating microbiome shifts in these three conditions.

Caries—Caries is the localized demineralization of dental hard tissues by acidic by-products derived from bacterial fermentation of dietary carbohydrates (73). If not controlled, the disease progresses resulting in the cavitation of the affected tooth, potentially allowing microbial colonization of the tooth pulpal tissue (74). Dental caries is a multifactorial disease in which the frequent intake of dietary carbohydrates and the subsequent generation of a low environmental pH drive alterations in the composition and metabolic properties of the bacterial communities in dental plaque, leading to the enrichment of acid producers (acidogenic) and acid-tolerant (aciduric) microorganisms (39, 75). The ecological plaque hypothesis, proposed to explain caries etiology, summarizes these dynamics (39). Prior to the onset of the disease, acidogenic bacteria present in the dental biofilm metabolize dietary fermentable sugars. The acid produced changes the local environment driving an ecological shift in the resident microbiota that favors the selection of aciduric species, which are able to tolerate, grow and continue to produce acid in low-pH environments. With the frequent intake of dietary sugars, and a more acidogenic and aciduric microbiome, the plaque pH is therefore maintained at low levels, promoting enamel demineralization (76).

Despite inter-subject variability, cariogenic plaques are enriched by a common but limited number of acidogenic/aciduric species compared to healthy subjects. Among these species, *Streptococcus mutans* shows the greater correlation with both onset and progression of caries (14, 77, 78, 79). However, besides *S. mutans*, increased abundance of other streptococci as well as species of *Actinomyces*, *Atopobium*, *Lactobacillus*, *Bifidobacterium*, *Propionibacterium* and *Scardovia* has also been associated with caries lesions (14, 77, 80, 81, 82, 83, 84, 85, 86, 87). A recent microbiome evaluation by Gross et al. (14) reported that *S. mutans* was the dominant species in many, but not all, subjects with caries. A different species from the Mutans group of streptococci (MS) (*Streptococcus sobrinus*), a phylotype from the Salivarius group of streptococci (*Streptococcus vestibularis/salivarius*) and a

species from the Mitis group of streptococci (*Streptococcus parasanguinis*) were also found in high levels in subjects with caries, especially in individuals with no or low levels of *S. mutans* (14). These findings indicate that the acidogenic activity of plaque is probably more important for lesion development than the presence of specific bacterial species. Thus, given the right ecological pressure, other species different from *S. mutans*, but with aciduric and acidogenic characteristics, could become significant contributors to the disease.

Periodontal diseases—Periodontal diseases are inflammatory conditions that affect the supporting structures of teeth. The interplay between biofilms that accumulate at the gingival margin and the resulting local immune responses results in gingival inflammation, that is, gingivitis. Further inflammation, as observed in periodontitis, results in destruction of the connective tissue attachment, alveolar bone resorption and eventual tooth loss (88). Periodontitis can be broadly classified as aggressive or chronic, based on clinical presentation and progression rate. Chronic periodontitis is generally detected in older subjects compared to more aggressive forms, has slower rates of progression and destruction, and is associated with ticker and more complex biofilms (89). Aggressive periodontitis is further divided into localized and generalized forms, the former typically affecting specific teeth (90).

The transition from health to periodontitis is characterized by shifts in the community structure of the subgingival microbiome, probably as a result of the interaction between resident communities and the inflammatory response of the host (13, 88, 91). Health-associated subgingival communities are enriched in Gram-positive taxa such as *Rothia* spp. and *Actinomyces* spp., while gingivitis communities are enriched with mostly Gram-negative species from the genera *Prevotella*, *Selenomonas* and *Fusobacterium*, among others (92, 93, 94). Further microbiome shifts occur as periodontitis develops with the establishment of a highly diverse community enriched in species such as *P. gingivalis*, *Tannerella forsythia*, *Treponema* spp., *Filifactor alocis*, and *Fretibacterium* spp., among many others (13, 95, 96, 97). Moreover, the aggressive form of periodontitis is characterized by elevated proportions of *Aggregatibacter actinomycetemcomitans* in addition to some of the mentioned bacterial species typically enriched in chronic periodontitis (98, 99, 100, 101, 102).

The exact mechanisms behind microbiome shifts associated with periodontal diseases have not been completely elucidated, but is likely that both microbial and host forces drive the community structure changes. Currently, the most accepted hypothesis of periodontal disease etiology is the polymicrobial synergy and dysbiosis model (88, 103). According to this model, low levels of keystone species such as *P. gingivalis* enhance microbial community virulence by disabling immune surveillance mechanisms in the gingival sulcus, allowing overall community overgrowth, which promotes inflammation. Inflammation further modifies the community selecting for “inflammophilic” organisms, which are those capable of metabolism of proteinaceous substrates derived from tissue breakdown and from GCF, the flow of which is increased in disease. Inflammation and dysbiosis reinforce each other, eventually causing destruction of periodontal tissues (88). Several mechanisms have been described to mediate the keystone pathogen-driven dysregulation of the host response. *P. gingivalis* has been shown to dysregulate pro-inflammatory signals in epithelial cells such

as the neutrophil chemokine IL-8 and the T-cell chemokine CXCL10/IP-10 (104, 105). Also *P. gingivalis*, together with *Prevotella intermedia* and *T. forsythia*, dysregulate via several mechanisms the complement pathway (88, 106, 107, 108, 109), with animal models showing that complement plays an essential role in the pathogenesis of periodontitis (110). Therefore, synergic interactions between species in the community, the decreased effectiveness of host surveillance mechanisms and the resulting enhancement of overall community growth with subsequent inflammatory responses conducive to connective tissue attachment and bone loss are likely to contribute to the onset of periodontitis.

Oral candidiasis—Oral candidiasis is the superficial inflammation of the oral mucosa due to the overgrowth of *Candida* spp. (111). Clinical presentations of the primary forms of oral candidiasis include: (i) acute pseudomembranous candidiasis; (ii) chronic erythematous candidiasis; (iii) acute erythematous candidiasis; and (iv) chronic hyperplastic candidiasis (112). *Candida albicans* is the most predominant species associated with oral candidiasis, followed by *Candida glabrata*, *Candida tropicalis*, *Candida parapsilosis*, *Candida kefyr*, *Candida dubliniensis*, *Candida lusitanae* (currently *Clavispora lusitanae*), *Candida krusei* (currently *Pichia kudriazevii* and *Issatchenkia orientalis*), and *Candida guilliermondii* (currently *Meyerozyma guilliermondii*) (113). However, the sole presence of these species in the oral cavity is not enough for disease onset. Oral candidiasis development is mostly driven by conditions that compromise the systemic immune response such as organ transplantation, HIV infection, chemotherapy, radiotherapy and advanced age. Other local contributory factors that may promote *Candida* overgrowth include wearing a removable prosthesis, poor oral hygiene, tobacco use and hyposalivation (111). Saliva seems to be a key element in the control of *Candida* overgrowth, since it has components such as soluble IgA and mucins that bind and clear the fungi from the oral cavity, as well as histatin 5 and calprotectin that have potent antifungal activities (114).

Contrary to other mucosal compartments, no clear relationship between the disruption of the bacterial component of the oral microbiome by the use of antibiotics and the overgrowth of *Candida* spp. in the oral cavity has been established. Our current understanding of fungal-bacterial ecology in relation to oral health and disease is limited. Current in vitro studies and animal models suggest that the interactions between *C. albicans* and bacterial partners such as oral streptococci may be synergistic rather than antagonistic (115, 116, 117). However, no longitudinal studies exist in humans evaluating fungal and bacterial microbiome interactions during oral candidiasis progression.

3. Overview of mechanisms behind common microbial therapeutic approaches

Microbial therapeutics include several approaches aimed at restoring the ecological balance through the use of viable cells. Such strategies have been applied with successful results mainly in gastrointestinal diseases and range from targeting specific species to the replacement of the entire microbiota. Among the strategies that use live cells as therapeutic agents and have been considered in the context of oral diseases are: (i) probiotics, (ii) bacterial replacement, and (iii) predatory bacteria and bacteriophages.

Probiotics—The World Health Organization, and the Food and Agriculture Organization of the United States define probiotics as “Live microorganisms which, when administered in adequate amounts, confer a health benefit on the host”. Some of the desirable characteristics of a probiotic strain include: non-pathogenic and safe for the patient, genetically stable, and able to survive processing and administration conditions. Other characteristics such as being able to adhere to mucus and/or human epithelial cells, having antimicrobial activity against potentially pathogenic bacteria and/or the ability to reduce pathogen adhesion to surfaces may also be desirable (118).

Although the exact molecular mechanisms of action of probiotics are largely unknown, proposed mechanisms can be summarized in three general areas: (i) enhancement of mucosal barrier function, (ii) modulation of the immune response, and (iii) antagonism of pathogens either by the production of antimicrobial compounds or through competition for mucosal binding sites (119, 120). The enhancement of the mucosal barrier is thought to be mediated by the interaction of microorganism-associated molecular patterns (MAMPs) with specific epithelial cell receptors (119). Also, several specific bacterial molecules have been shown to direct the expression of tight-junction proteins protecting epithelial cells from apoptosis and promoting cellular proliferation (121), suppress intestinal inflammation through the activation of the histamine H2 receptor (122), and reduce the recruitment of T helper 17 (Th17) cells down-regulating interleukin 17 (IL-17) cytokine production (123). Fungal probiotics such as *Sacharomyces boulardii* have been shown to improve gut barrier function and decrease the inflammation tone reducing body weight, fat mass, and hepatic steatosis in obese and Type 2 diabetic mice (124, 125, 126, 127). Another example of an immunomodulatory probiotic effect is the production of a cell surface-associated exopolysaccharide (EPS) by *Bifidobacterium breve* that protects against infection with enteric pathogens in mice by inducing alterations in antibody production (128).

The direct antagonist effects of probiotics on potentially pathogenic species are possibly mediated by competition for nutrients or adherence, and via direct antimicrobial activity (129, 130, 131, 132). Although some direct probiotic-pathogen interactions have been documented, whether probiotics need to change the composition of the microbiota to exert their effect remains controversial. Probiotic-induced changes in microbial composition towards beneficial bacteria have been shown in both obesity and hepatocellular carcinoma models (123, 124), while McNulty et al. (133) showed that the metabolic function of the community changed without alterations in community membership after treatment of mice with a mixture of probiotics.

A list of diseases in which probiotic use is most accepted as some beneficial effect has been found includes: treatment of infectious childhood diarrhea, prevention of antibiotic-associated diarrhea, prevention and maintaining remission in pouchitis, treatment and maintenance of remission in ulcerative colitis, treatment and prevention of atopic eczema associated with cow's milk allergy, and hepatic liver disease. The recommendations for use of probiotics are strain specific and mostly include *Lactobacillus* and *Bifidobacterium* spp. (134, 135, 136).

Bacterial replacement therapies—Bacterial replacement therapies are based on the utilization of indigenous bacteria, usually genetically modified, to colonize human tissues and thereby prevent the outgrowth of disease-associated microorganisms (137, 138). The “effector” bacterial strain is normally an isolate from a human reservoir modified using genetic tools with the purpose of incorporating some beneficial properties. Desirable characteristics for an effector microbial strain have been summarized as: (i) to be specifically active against target pathogens without significantly disturbing the balance of the existing microbial ecosystem, (ii) indigenous and able to survive in the selected habitat and/or ecosystem and not elsewhere, (iii) non-pathogenic (or weakly opportunistic) for the host species, (iv) susceptible to low-risk antibiotics such as penicillin so that the strain can be later eliminated if desired, (v) easily propagated and readily prepared in a stable form for commercial distribution, (vi) easily identifiable among the resident microbiota, (vii) not causing systemic toxicity or immunological sensitization in the host or leading to selection of resistant microorganisms, (viii) capable of persisting in the host tissues to effect long-term protection (138).

In comparison to probiotics, less research has been conducted to create and evaluate genetically modified effector strains to prevent or treat human disease. Examples of studies using this approach include the evaluation of the role of genetically modified strains of *S. mutans* in the prevention and/or treatment of caries (139, 140). Additionally, studies have been published evaluating the effect of non-genetically modified strains that may out-compete pathogens when administered; for example, a nasal spray containing a mixture of *S. sanguinis*, *S. mitis* and *S. oralis* showed promise as a therapeutic alternative for acute otitis media in children (141).

A relatively new strategy that utilizes the bacterial replacement principles for the treatment of dysbiotic disorders is whole microbiome transplantation, also called ecotherapeutics. This strategy has been mainly directed towards the restoration of the intestinal microbiota after antibiotic treatment, which alters the indigenous community structure and allows colonization by pathogens such as *Clostridium difficile* (142). Ecotherapeutics include mostly fecal transplantation, which consists of administration of stool from a healthy donor to the symptomatic patient (143). Fecal transplantation has been tested as a therapy for *C. difficile*-associated diarrhea with excellent clinical results, showing restoration of bacterial diversity in stool samples and a decrease in symptomatology with a much more superior performance than vancomycin treatment, which has been the standard of care (144, 145). Also, some promising results have been obtained for other conditions such as metabolic syndrome, obesity, ulcerative colitis and irritable bowel syndrome (146, 147, 148, 149, 150).

Transplantation of selected members of the community also appears as a future viable alternative for the treatment of some dysbiotic diseases. The identification of specific strains with a probiotic-like capacity within the indigenous microbiome and subsequent administration seems a promising strategy. Experiments in mice have shown that oral administration of a cocktail of human intestinal clostridia is able to induce regulatory T (Treg) cells and anti-inflammatory molecules, and attenuated disease in models of colitis and allergic diarrhea (151). Another approach involves the identification of indigenous microorganisms that confer resistance to infection by exogenous pathogens after antibiotic

treatment, and that could thus be administered prophylactically with the aim of enriching them in the microbiome. For instance, the bile acid 7 α -dehydroxylating intestinal bacterium, *Clostridium scindens*, has been shown to be associated with resistance to *C. difficile* infection when it forms part of the native gut microbiome, and enhances resistance to post-antibiotic infection when administered exogenously (152). These studies highlight the possibility of using indigenous effector bacteria that specifically modulate the inflammatory response and/or antagonize pathogenic strains and are habitat-specific.

Predatory bacteria and bacteriophages—Predatory bacteria consist of a diverse group of obligatory predators widely distributed in aquatic and terrestrial environments (153). The most studied strain is *Bdellovibrio bacteriovorus* HD100, which is a predator for Gram-negative species. After attaching to its prey, the predator invades its periplasmic space and multiplies while destroying its cytoplasm. Once the multiplication cycle is completed, the predator destroys the rest of the prey's cell and releases its progeny (154).

Beside *B. bacteriovorus*, a number of strains of predatory bacteria called Bdellovibrio-and-like-organisms (BALOs) have received attention as antibacterial agents for the control of pathogenic bacteria. Among the characteristics that make these species good candidates for the control of diseases are: (i) non-pathogenic and non-toxic in several mammals models; (ii) potentially well tolerated by humans; (iii) able to attack a wide range of Gram-negative bacteria; (iv) able to attack both planktonic and biofilm cells; (v) able to attack their prey even in presence of Gram-positive bacteria (155).

The characteristics listed above make BALOs candidate antibacterial agents for the treatment of a number of Gram-negative associated diseases. Several studies have reported killing activity of BALOs against a wide range of bacteria such as *Helicobacter pylori* and *Campylobacter jejuni* (156), as well as against bacteria associated with ocular infections (157), and periodontitis (158, 159). However, no human studies have been performed with BALOs, and only one study has demonstrated efficacy *in vivo*, showing that both cecal inflammation and colonization by *Salmonella enterica* serovar Enteritidis was reduced in chicken treated with *Bdellovibrio* (160).

Bacteriophages are viral particles that infect bacteria leading either to lytic or lysogenic cycles. Lytic (virulent) phages once replicated and assembled, rapidly destroy the bacterial cell, releasing their progeny (161). Because of their ability to kill bacteria, lytic phages have been historically used for treating infectious diseases such as dysentery, skin and urinary tract infections, among others (reviewed by Abedon et al. (162)). Several studies have been conducted with phages to prevent the formation of *in vitro* biofilms of *Pseudomonas aeruginosa*. Although initially promising results were obtained in one of these studies, regrowth of the biofilm after 24 hours of phage administration was observed (151). As an alternative, cocktails of phages or combinations of the viral particles with other antimicrobial agents were investigated with better efficiency at destroying biofilms (163, 164, 165). The efficacy of phage cocktails has also been tested in human trials for otitis and wound infections, which showed some clinical improvements and no adverse effects (166, 167).

4. Application of microbial-based therapies to oral diseases

Current strategies for treatment of caries and periodontal diseases are focused on the mechanical removal of dental plaque and associated deposits, complemented with the use of antimicrobial compounds and, in the case of caries, with diet modification, topical fluoride application and, if needed, restoration of damaged tooth structures (73, 168, 169, 170). The main limitation of such strategies is that only a temporary modification of the pathogenic communities is achieved after therapy with the disease-associated microbiota, in some individuals, recovering shortly after the initial therapeutic intervention (86, 171, 172). It is also not clear whether the oral microbiome is completely restored, even short-term, by these treatment strategies to a composition similar to that of a healthy subject that never experienced the disease. Oral candidiasis is mostly treated with antifungal agents, some of which select for strains of *Candida* spp. resistant to such antimicrobial agents (173, 174). Therefore, there is a current need for preventive and therapeutic strategies for oral diseases that aim at restoring a healthy microbiome and increase its resistance to dysbiotic perturbations.

Microbial therapeutics for caries—Attempts have been made to apply replacement therapies for the management of dental caries using potential effector strains with decreased acidogenicity, such as an *S. mutans* strain defective in intracellular polysaccharide (IPS) metabolism (140), a non-cariogenic *S. salivarius* strain called TOVE-R (175), and an *S. mutans* strain deficient in lactate dehydrogenase activity (176). These strains were used in studies that evaluated their antagonistic activity against native acidogenic *S. mutans* and other caries-associated species, their ability to persistently colonize the oral cavity, their safety and non cariogenicity, and the possibility to be eradicated if needed (139, 175, 177, 178).

The group of Jason M. Tanzer conducted studies with both an *S. mutans* defective in IPS metabolism and the non-cariogenic *S. salivarius* TOVE-R. The IPS-deficient *S. mutans* mutant was shown to prevent the colonization by two caries-associated strains of *S. mutans* and *S. sobrinus*, in *S. mutans*-free conventional rats (140), but no further studies were conducted. *S. salivarius* TOVE-R was demonstrated to partially displace both *S. mutans* and *S. sobrinus* pathogenic strains in a rat model, accompanied by a decrease in caries experience (175, 179). Some *in vitro* studies were conducted to characterize its mechanism of action (180) but, probably because of lack of genetic information on the strain, further studies in humans were not performed.

The group of Jeffrey D. Hillman isolated the *S. mutans* strain JH1001 which produced a bacteriocin, mutacin 1140, able to inhibit the *in vitro* growth of a wide range of bacteria including caries-associated species of *Streptococcus*, *Actinomyces* and *Lactobacillus* (176, 181). The effector strain failed to consistently colonize the human oral cavity, thus a mutant that produced higher levels of mutacin 1140 was constructed, thereby improving its colonization and competition with indigenous *S. mutans* (177, 182). Subsequent genetic modifications of the bacteriocin-producing strain were conducted, obtaining a less cariogenic strain due to deletion of lactate dehydrogenase activity (139). Further mutations were later introduced consisting of the deletion of the *dal* gene, involved in D-alanine

biosynthesis, and the *comE* gene involved in the uptake of environmental DNA (178). This last strain (A2JM) was expected to be non-cariogenic, able to displace oral cariogenic microorganisms, less prone to transformation and dependent on the exogenous addition of D-alanine, a property to allow control of its growth in the host via the exogenous administration of the amino acid. Although subsequent studies showed it was possible to eradicate the effector strain A2JM in a rat model, the genetically-modified strain did not have greater genetic stability than the parental strain and no studies in humans have been reported (178).

The evaluation of the effectiveness of probiotics as anticariogenic agents has been subject of high attention for the last 20 years. Despite an increasing number of publications in the field, only a small proportion of these studies have evaluated the effects of probiotics in human clinical trials. Stensson et al. (183) showed that the administration of *Lactobacillus reuteri* during the first year of life was associated with a decrease in caries prevalence at 9 years of age. Moreover, studies have shown that the administration of *Lactobacillus* and/or *Bifidobacterium* strains has a positive short-term effect decreasing MS counts in saliva (184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199). Other studies, however, have found that MS counts in plaque and/or saliva samples do not change or increase after probiotic intake (200, 201, 202, 203, 204). Also, changes in acidogenicity were not observed in plaque or saliva after probiotic use (201, 202). Long-term evaluation of probiotic administration has also shown contradictory results. While a reduction in caries incidence and/or MS counts was shown to occur after 10 or 12 months of ingestion of lactobacilli (205, 206), intervention early in life with *Lactobacillus* or *Bifidobacterium* spp. had no effect on occurrence of caries and/or on MS counts up to 4 years after the administration (207, 208). Even though the study of potentially probiotic bacteria focuses mostly on lactobacilli, other human indigenous species from the genera *Pediococcus*, *Leuconostoc*, and *Streptococcus* have also been proposed to have probiotic effects against caries (209, 210). *S. salivarius* M18 and a mouthwash containing a mixture of *S. oralis* KJ3sm, *Streptococcus uberis* KJ2sm and *Streptococcus rattus* JH145 (a spontaneous lactic acid deficient mutant) have been shown to decrease levels of MS (211, 212). Gruner et al. (213) recently performed a meta-analysis with the data available from randomized controlled trials published between 1967 and June of 2015, regarding the use of probiotics in caries, considering human studies that included a control group of either placebo or alternative treatments. Although, the analysis showed that probiotics were associated with reductions in the counts of *S. mutans*, the authors found no significant reduction in caries experience, concluding that currently there is no sufficient evidence for recommending probiotics in either prevention or treatment of caries.

More recently, investigations on caries have focused on finding a rationally-designed strategy to alter tooth plaque metabolism towards that of a microbial community compatible with health. Clinical studies in children with different caries experience have shown that plaque alkali production may be related to caries susceptibility with plaque from healthy children showing a greater ability to produce alkali via the arginine deaminase system (ADS) than plaque from children with caries lesions (214, 215). A limited number of oral species are capable of metabolizing arginine via the ADS with alkali generation. Most species identified belong to the genus *Streptococcus* with *S. sanguinis* strains being very

prevalent among ADS-positive isolates (216). Moreover, a highly arginolytic strain of *Streptococcus* belonging to a potentially novel species was isolated from supra-gingival plaque of a caries-free individual. The strain not only expressed the ADS pathway at high levels under a variety of conditions but also effectively inhibited the growth and two intercellular signaling pathways important in *S. mutans* (217). These studies show that strains capable of alkali production via arginine may be important contributors to the stability of healthy communities and have prompted investigators to consider if the exogenous administration of arginine may have a beneficial effect in enriching for a health-compatible dental plaque community. Indeed, a clinical study showed that the use of an arginine-containing toothpaste significantly increased ADS activity in plaque of caries-active individuals and shifted the bacterial composition to a healthier community, more similar to that of caries-free individuals (218). These investigations show that arginine could potentially serve as an anti-cariogenic agent and that perhaps the combination of exogenous arginine administration and enrichment of the microbiome with ADS-positive strains could potentially have a health benefit.

In summary, the management of caries with bacterial replacement therapies based on genetically modified strains has not advanced into clinical trials. Meanwhile, several clinical studies have been conducted with various probiotic combinations but results are mixed and so far are insufficient for recommending their use in caries management. The use of probiotics for caries prevention does not seem to be derived from a clear rationale as probiotics may not antagonize the local acidogenic microbiota, and the strains themselves have a potential for acidogenicity. Recent efforts focused on defining the metabolic properties of microbial communities associated with health seem to offer more promise, with therapies aimed at the enrichment of alkali production via arginine metabolism representing a more rational alternative.

Microbial therapeutics for periodontal diseases—In the case of periodontal diseases, oral or exogenous probiotic strains have been evaluated under the assumption that they could help in the suppression of periodontitis-associated species by the production of antimicrobial substances or via competitive exclusion mechanisms, and also contribute to modulation of immune responses (219, 220). Different bacterial strains have shown beneficial immunomodulatory effects with respect to the periodontium. These include species like *S. salivarius* and *Streptococcus cristatus* in *in vitro* studies (221, 222, 223), and *Lactobacillus brevis* CD2 in animal models and in humans with periodontitis (224, 225). *S. cristatus* has been shown to attenuate the expression of cytokines such as IL-8, IL-1 α , IL-6 and tumor necrosis factor- α (TNF- α) in epithelial cells in response to *Fusobacterium nucleatum* (222, 223), while *S. salivarius* K12 has been shown to inhibit the secretion of IL-8 in response to several MAMPs (221). In both mice and humans, *L. brevis* has been shown to decrease levels of inflammatory markers like prostaglandin E-2 (PGE-2), γ -interferon (IFN- γ), TNF- α , IL-1 β , IL-6 and IL-17A (224, 225).

The antimicrobial effects of probiotic-like strains against bacterial species associated with periodontal diseases have also been studied. Among these, a hydrogen peroxide-producing *S. sanguinis* strain has been shown to suppress *A. actinomycescomitans* *in vitro* and antagonize its colonization in gnotobiotic rats (226). *In vitro* studies have also shown that

species such as *S. sanguinis*, *S. cristatus*, *S. salivarius* and *S. mitis* inhibit colonization of epithelial cells by *A. actinomycetemcomitans* (227, 228), while in another study *S. sanguinis*, *S. salivarius*, *S. mitis*, *Actinomyces naeslundii*, and *Haemophilus parainfluenzae* reduced the adhesion of *P. gingivalis* to the bottom plate of a parallel plate flow chamber, but failed to significantly inhibit *A. actinomycetemcomitans* (229). Bifidobacteria species isolated from saliva samples of periodontally healthy individuals have also been shown to inhibit *P. gingivalis* growth possibly by competing for vitamin K (230).

Human clinical studies on the effect of *Lactobacillus* spp. probiotics in the treatment of chronic periodontitis have reported statistically significant improvements in periodontal clinical parameters such as plaque index, bleeding on probing and pocket depth and/or reduction of periodontitis-associated species when utilized alone (231, 232), or as an adjunct to periodontal treatment, in comparison to a control group (232, 233, 234). However, another study reported that the adjunctive use of a probiotic tablet, containing *Streptococcus oralis* KJ3, *Streptococcus uberis* KJ2 and *Streptococcus rattus* JH145, did not significantly improve the therapeutic outcomes of scaling and root planing when compared to the placebo group (235). In subjects with gingivitis, the use of probiotics has shown a positive clinical effect in some studies (236, 237, 238), while Iniesta et al. (239) reported decreased levels of *P. intermedia* in saliva, and *P. gingivalis* in subgingival plaque, but no improvements in plaque and gingival indexes after probiotic administration. Moreover, in healthy children subjected to complete oral prophylaxes followed by probiotic administration in the form of curd, no differences in gingival health were observed in comparison to the control (240). Other studies report that probiotic administration has a positive effect reducing inflammatory markers in GCF or decreasing levels of periodontitis-associated microorganisms (241, 242, 243).

The previously mentioned meta-analysis by Gruner et al. (213) of data available on probiotics trials between 1967 and June of 2015 also included periodontal diseases as an outcome. This evaluation revealed that while the use of probiotics for periodontal disease management did not significantly affect the counts of *A. actinomycescomitans*, *P. gingivalis* and *P. intermedia*, it improved two clinical markers indicative of inflammation, that is bleeding-on-probing and gingival index and helped in reduction of pocket probing depth (213). In summary, most studies report a small but potentially beneficial effect of the use of probiotics in reducing risk factors associated with periodontal diseases, or when used as adjuncts to periodontal therapy, with most positive outcomes associated with the use of lactobacilli.

Attempts to recolonize the subgingival environment with health-associated bacteria as part of periodontal therapy were conducted by Teughels et al. (244), who evaluated the effect of administering a mixture of *S. sanguinis*, *S. salivarius* and *S. mitis* strains as adjuvants in subgingival artificially-created pockets in beagle dogs. Four months after the pockets were induced, different treatments consisting of either subgingival scaling and root planning (Rp), root planning and a single topical application of the streptococci mixture (Rpsingle), or root planning followed by three successive topical applications of the bacterial mixture (Rpmulti) were evaluated. The effect of each treatment was evaluated after 12 weeks and the results were compared with an untreated control group. Although significant reductions in pocket

depth, bleeding on probing, and clinical attachment level were observed in the three treatment groups, the improvements were greater in the Rp_{multi} group. The Rp_{multi} dogs also showed the most dramatic reduction in anaerobic and black-pigmented species including *Porphyromonas gulae* (a canine form of *P. gingivalis*), *P. intermedia* and *Campylobacter rectus*, and a lesser tendency for reemergence of these pathogens after 12 weeks (244), together with a significant increase in bone density (245). Although the authors did not evaluate whether the streptococci actually colonized the subgingival environment, it is worth noting that streptococci represent a minor genus in dogs (246, 247), and therefore the administration of human streptococci to dogs could be considered an exogenous microbial implantation rather than a restoration of indigenous microbiota. These experiments constitute perhaps one of the few attempts to evaluate if enrichment of the microbiome with species associated with periodontal health could have a beneficial effect.

Despite the knowledge that periodontitis is associated with a profound dysbiosis of the subgingival microbiome, no attempts at whole subgingival microbiome transplantation as a treatment of periodontal disease are found in the literature. Only one report shows research towards a possible application of microbiota transplantation in the oral cavity (248). In this study the authors tested an antimicrobial approach to decrease oral bacterial load in preparation for future whole microbiome transplantation. The report shows that the use of sodium hypochlorite was effective at reducing the numbers of oral bacteria and its antimicrobial effect could be inactivated by a non-toxic sodium ascorbate – ascorbic acid buffer.

A potentially interesting approach that has been evaluated in the context of periodontal diseases is the use of BALOs since periodontitis-associated dysbiosis is mostly due to an overgrowth of Gram-negative species. *B. bacteriovorus* HD100 has been shown to significantly reduce the number of viable *A. actinomycetemcomitans* both in planktonic and biofilm in vitro cultures (249). The eradication of *A. actinomycetemcomitans* from biofilms by predators, however, is not complete, but the combination of BALOs with an exopolysaccharide-hydrolysing enzyme has been shown to be more effective at decreasing the levels of *A. actinomycetemcomitans* (158). Other studies have shown that different strains of *B. bacteriovorus* may be required to effectively antagonize other Gram-negative species such as *P. intermedia*, *P. gingivalis* and *Capnocytophaga sputigena* (158, 159). Moreover, the presence of saliva and other non-target bacteria such as the Gram-positive health-associated *A. naeslundii* have been shown as non-inhibitory to the predatory activity (159). The effect of *Bdellovibrio* has also been tested in a more complex context such as a 6-species community formed by *P. intermedia*, *A. actinomycetemcomitans*, *P. gingivalis*, *F. nucleatum*, *S. mitis* and *A. naeslundii*, as well as against saliva or subgingival plaque samples. In both cases, although it was observed that the efficiency of predation decreased as the complexity of the models increased, the predator was effective at decreasing the levels of *F. nucleatum* and *A. actinomycetemcomitans* but other species such as *P. gingivalis* were not affected (250). Importantly, the predatory activity of BALOs was shown to be completely abolished under oxygen-limiting conditions since BALOs are strict aerobes (159, 251). This is a relevant aspect and questions their true potential to eliminate periodontitis-associated species in the reduced conditions that exist in periodontal pockets. In summary, although BALOs

show promising in vitro results, especially in the control of *A. actinomycetemcomitans*, their effectiveness has not been tested *in vivo*.

Evaluations of the oral virome have revealed that the oral cavity harbors a great amount of bacteriophages (252, 253, 254). Although some efforts have been conducted to elucidate the contribution of viruses in the shifts associated with oral diseases, their role in dysbiosis remains unknown (255, 256). Differences in virome community structure were found between health and periodontal disease, in both subgingival and supragingival plaque but not in saliva, with higher proportions of lysogenic *Syphoviridae* in health while lytic viruses from the *Myoviridae* family were enriched in disease (256). These observations suggest that an altered virome is part of the dysbiosis associated with periodontitis. Despite the potential use of phages as antimicrobial agents against oral pathogens, only a few studies have focused on discovering phages for the control of periodontal dysbiosis (257, 258). Phages isolated from saliva and waste water from dental chair drainages showed antimicrobial activity against planktonic *F. nucleatum* or *A. actinomycetemcomitans* in in vitro biofilms, suggesting a potential application in gingivitis or aggressive periodontitis, which are diseases associated with these respective species (257, 258).

Microbial therapeutics for oral candidiasis—Several in vitro studies show probiotics may affect the virulence potential of *C. albicans*. *Lactobacillus* spp. and *S. salivarius* have been shown to negatively impact *C. albicans* yeast-to-hyphae differentiation and/or biofilm formation (259, 260). The mechanism of action would not depend on probiotic-yeast contact, because the use of sterile-filtered supernatant obtained from *S. salivarius* and *Lactobacillus* spp. significantly down regulates, in *C. albicans*, genes critical for the yeast–hyphae transition, biofilm formation, host cell invasion and virulence (261, 262). Also, the treatment of an engineered human oral mucosa tissue model with *Bacillus subtilis* has been shown to decrease *C. albicans* attachment (263).

Animal models have been used to demonstrate potential antagonistic effects of probiotic-like strains on *C. albicans*. *L. acidophilus* protected *Galleria mellonella* larvae against experimental candidiasis (262), while in immunosuppressed mice, *L. rhamnosus* reduced oral *C. albicans* colonization to a higher extent than the antifungal nystatin (264). Moreover, oral administration of *L. acidophilus* to mice has been shown to significantly shorten the duration of *C. albicans* colonization in the mouth, possibly due to an immunomodulatory effect (265). It has also been shown that the application of heat-killed *Enterococcus faecalis* to the tongue of immunosuppressed mice reduces both symptoms and *Candida* counts (266).

Human studies support the mentioned in vitro and animal studies, with positive reported effects for probiotic intake with regards to the risk of developing oral candidiasis. Salivary levels of yeast in elderly subjects have been shown to decrease compared to basal levels after probiotic intake (267, 268, 269), together with a significant increase in anti-*Candida* IgA levels (269). In patients diagnosed with oral candidiasis, the local administration of a mixture of *Bifidobacterium longum*, *Lactobacillus bulgaricus* and *Streptococcus thermophilus* was shown to improve oral pain and reduced the prevalence of *Candida* spp. compared with conventional antifungal therapies (270). Moreover, in asymptomatic denture

wearers harboring oral *Candida* spp., yeast detection was reduced in the probiotic group compared to placebo (271).

5. Limitations of current microbial therapeutic approaches for oral diseases and perspectives for development of new strategies

Positive but discrete results have been reported for the management of oral diseases using microbial-based therapies. Most microbial-based therapies evaluated in clinical studies are in the probiotic category with studies showing some small clinical benefits but lack of defined mechanisms of action. The use of probiotic-like strains seems more beneficial for periodontal diseases and oral candidiasis than for caries (213, 270, 271). Both periodontal diseases and candidiasis are associated with an increased inflammatory response (88, 111), and it is likely that probiotic-mediated immune modulation mediates such favorable effects. It is not clear, however, if the probiotic strains are indeed incorporated into the local microbiota, whether their effect is related to their direct interaction with oral tissues or if their effects are related to interactions with distant mucosal cells in the gastrointestinal tract and systemic immune modulation. It is also worth noting that although most clinical studies reviewed showed trends towards a positive effect of probiotics as adjuncts to periodontal therapy and in reducing oral yeast carriage, adequately powered and high quality clinical studies are scarce. Furthermore, the effect size in all studies testing probiotics seems rather small questioning the clinical relevance of their administration.

The development of more rationally-designed microbial-based therapies for oral diseases is still in its infancy but offers more promise than the indiscriminate use of non-specific probiotic strains. Oral diseases are associated with dysbiosis and therefore, preservation or restoration of the homeostatic state promoted by a health-associated community is the ultimate preventive and therapeutic goal. As reviewed in Figure 1, unique mechanisms mediate the microbiome shifts associated with caries, periodontal diseases and oral candidiasis. It is conceivable to think that microbial therapeutics could contribute to the prevention and treatment of these conditions via promotion of the growth of a health-associated community. The implantation of selected oral strains representing health-associated taxa, or the re-implantation of a sample from the same patient but enriched with health-promoting strains are alternatives together with whole microbiome transplantation. One of the challenges, however, of using microbial-based therapies in the mouth compared to the gut, is the potential for their rapid loss from the oral cavity by swallowing before they have had a chance to become established and/or exert an effect. The potential advantage of using indigenous oral species as microbial therapeutics is their greater potential to colonize the specific habitat from which were they were extracted, compared to exogenous strains. It is however clear that even if a health-associated community is obtained via such transplantation approaches or through selected killing of disease-associated species, a long-term effect would not be attained unless the environmental and host-related risk factors shown in Figure 1 are modified. Microbial therapeutics are therefore conceivable only within the context of a more holistic preventive approach involving several strategies.

In the case of caries, research involving microbial-based therapies has focused on competition and/or suppression of *S. mutans*. However, it is important to recognize that in

the absence of *S. mutans*, other acidogenic/aciduric species could become enriched given the right environmental pressure (frequent carbohydrate intake). Thus, more attention should be put on the control of the acidification of dental biofilms rather than in the elimination of specific species. A conceivable microbial-based therapy for caries could be the enrichment of the microbiome with indigenous strains that counter-act acid-production and therefore promote health-associated species, such as the recently isolated arginolytic strain of *Streptococcus* (217). Exogenous administration of such strains together with arginine oral supplementation may prove beneficial for caries prevention. The question, however, is whether such a strain, although native to the oral cavity of humans, can effectively colonize another host with an already assembled, organized and interacting microbiome community in which the specific niche is already occupied. Also, since the highly arginolytic strain is also a streptococcus it is possible that under carbohydrate pressure it may become acidogenic. It is thus clear that even if such a microbial-based therapy becomes a reality for caries management, it should be part of a holistic preventive approach with a focus on carbohydrate intake modification (see Figure 2).

In the case of periodontal diseases, current traditional therapies are directed towards controlling the subgingival microbial load. The use of mechanical and chemical means to control biofilm accretion is effective at preventing gingivitis and maintaining periodontal stability after therapy in most patients suffering from the disease but constitutes by no means a highly effective strategy as it depends on patient compliance. Desirable microbial-based therapeutics for periodontal diseases would be those that prevent the microbiome shifts associated with dysbiosis. In this respect strategies to antagonize the establishment of keystone pathogens such as *P. gingivalis* are desirable; however, more knowledge is required regarding inter-bacterial interactions in subgingival plaque and the identification of antagonistic species. For instance, *P. gingivalis* has the ability to sense extracellular arginine deiminase produced by *S. cristatus* and *S. intermedius*, responding by down-regulating the expression of key surface structures required for colonization (272, 273). Indeed, a negative correlation between the distribution of *S. cristatus* and *P. gingivalis* has been observed in subgingival plaque, suggesting that this antagonistic interaction may be important during *in vivo* community maturation (274). Moreover, understanding subgingival microbiome metabolic dynamics could uncover species that are important for overall community stability and increase the resilience of a health-associated community. This implies the application of a systems biology approach to study the microbiome focusing on the construction and analysis of *in silico* system-level metabolic models (275). Our field currently has information derived from omic's studies that can be used to reconstitute the metabolic frameworks of oral bacteria in relation to oral diseases. Such metabolic models may allow prediction of the role that each species may have in the health- and/or disease-associated consortia (5, 276, 277, 278). As with caries, however, microbial therapeutics for periodontal diseases may be just a part of a broader approach that should also include immune modulation, as it seems microbiome shifts associated with periodontitis are initially the result of immune dysregulation and are perpetuated by uncontrolled inflammation (Figure 2). Examples of targeted anti-inflammatory strategies against periodontitis include resolvins, anti-complement and anti-IL17, which directly address the disease immune-mediated pathophysiology (110, 279).

Although highly experimental, whole oral microbiome transplantation is a strategy that should be tested in the context of oral diseases. Such treatment may have an application in the restoration of homeostasis in patients suffering from periodontitis in which a profound microbiome shift has led to the establishment of a resilient pathogenic community. It should be considered, however, that the transplantation of an entire community may generate unexpected outcomes such as nonspecific immune responses either locally as result of the community implantation in the oral cavity, or systemic if certain species migrate to extra-oral sites. Another non-desired effect may be unexpected interactions between the implanted microbiota components and the indigenous species that could favor the growth of potentially pathogenic species. The question about what constitutes a healthy community is also an aspect that needs to be considered. Both community composition and function in the donor needs to be evaluated before transplantation, but there are no defined thresholds to define a health-promoting microbiome. On the other hand, an advantage of whole microbiome transplantation is that an entire community may have more chances to establish and compete with a pathogenic community than the administration of selected species. Disruption of the native pathogenic community would probably be necessary for the establishment of the transplanted one and therefore whole microbiome transplantation should be part of a treatment approach aimed at decreasing the microbial load by mechanical means or antimicrobial strategies. Also important for the long-term stability of the transplanted health-associated community would be that environmental factors such as the inflammatory exudate are controlled as eventually the newly established community could also become dysbiotic.

In the case of oral candidiasis, little knowledge is available regarding the role of other microbiome members on *Candida* overgrowth. While it is clear that immune dysregulation at the oral mucosal barrier promotes the outgrowth of *C. albicans*, the main species associated with candidiasis, it is less clear whether bacteria or other oral fungi contribute to or antagonize *Candida*. Such information can be obtained from longitudinal studies evaluating microbiome dynamics during oral candidiasis and would be essential for the possible development of microbial-based therapeutic adjuvants to prevent or treat candidiasis. Once again, such microbial adjuvants would require enhancement of mucosal immunocompetence in a combined strategy to prevent candidiasis (Figure 2).

6. Concluding remarks

In this review we discussed current approaches based on the use of live microbial strains for the manipulation of oral microbial populations to maintain host-microbe homeostasis. Novel strategies that consider not only the composition of communities associated with disease, but also the pathogenic functions may be more promising for the management of oral dysbiosis. However, the design of such strategies necessitates a deeper understanding of the inter-microbial interactions involved in the transitions from health to disease and those interactions important to maintain the stability and that confer resilience to health-associated communities. Any microbial-based therapeutic strategy aimed at oral conditions, however, should be part of a holistic approach to control the environmental factors that are primarily responsible for microbiome shifts.

Acknowledgments

The authors would like to acknowledge support from grants R01 DE021578 and R21 DE023967 from the National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health.

References

1. Chen T, Yu WH, Izard J, Baranova OV, Lakshmanan A, Dewhirst FE. The Human Oral Microbiome Database: a web accessible resource for investigating oral microbe taxonomic and genomic information. Database (Oxford). 2010; 2010:baq013. [PubMed: 20624719]
2. Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner AC, Yu WH, Lakshmanan A, Wade WG. The human oral microbiome. J Bacteriol. 2010; 192:5002–5017. [PubMed: 20656903]
3. Dupuy AK, David MS, Li L, Heider TN, Peterson JD, Montano EA, Dongari-Bagtzoglou A, Diaz PI, Strausbaugh LD. Redefining the human oral mycobiome with improved practices in amplicon-based taxonomy: discovery of *Malassezia* as a prominent commensal. PLoS One. 2014; 9:e90899. [PubMed: 24614173]
4. Lepp PW, Brinig MM, Ouverney CC, Palm K, Armitage GC, Relman DA. Methanogenic Archaea and human periodontal disease. Proc Natl Acad Sci U S A. 2004; 101:6176–6181. [PubMed: 15067114]
5. Yost S, Duran-Pinedo AE, Teles R, Krishnan K, Frias-Lopez J. Functional signatures of oral dysbiosis during periodontitis progression revealed by microbial metatranscriptome analysis. Genome Med. 2015; 7:27. [PubMed: 25918553]
6. Mark Welch JL, Rossetti BJ, Rieken CW, Dewhirst FE, Borisy GG. Biogeography of a human oral microbiome at the micron scale. Proc Natl Acad Sci U S A. 2016; 113:E791–800. [PubMed: 26811460]
7. Zijng V, van Leeuwen MB, Degener JE, Abbas F, Thurnheer T, Gmur R, Harmsen HJ. Oral biofilm architecture on natural teeth. PLoS One. 2010; 5:e9321. [PubMed: 20195365]
8. Marsh PD, Moter A, Devine DA. Dental plaque biofilms: communities, conflict and control. Periodontol 2000. 2011; 55:16–35. [PubMed: 21134226]
9. Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defining the normal bacterial flora of the oral cavity. J Clin Microbiol. 2005; 43:5721–5732. [PubMed: 16272510]
10. Diaz PI, Dupuy AK, Abusleme L, Reese B, Obergfell C, Choquette L, Dongari-Bagtzoglou A, Peterson DE, Terzi E, Strausbaugh LD. Using high throughput sequencing to explore the biodiversity in oral bacterial communities. Mol Oral Microbiol. 2012; 27:182–201. [PubMed: 22520388]
11. Frandsen EV, Pedrazzoli V, Kilian M. Ecology of viridans streptococci in the oral cavity and pharynx. Oral Microbiol Immunol. 1991; 6:129–133. [PubMed: 1945494]
12. Xu X, He J, Xue J, Wang Y, Li K, Zhang K, Guo Q, Liu X, Zhou Y, Cheng L, Li M, Li Y, Li Y, Shi W, Zhou X. Oral cavity contains distinct niches with dynamic microbial communities. Environ Microbiol. 2015; 17:699–710. [PubMed: 24800728]
13. Abusleme L, Dupuy AK, Dutzan N, Silva N, Burleson JA, Strausbaugh LD, Gamonal J, Diaz PI. The subgingival microbiome in health and periodontitis and its relationship with community biomass and inflammation. ISME J. 2013; 7:1016–1025. [PubMed: 23303375]
14. Gross EL, Beall CJ, Kutsch SR, Firestone ND, Leys EJ, Griffen AL. Beyond *Streptococcus mutans*: dental caries onset linked to multiple species by 16S rRNA community analysis. PLoS One. 2012; 7:e47722. [PubMed: 23091642]
15. Cephas KD, Kim J, Mathai RA, Barry KA, Dowd SE, Meline BS, Swanson KS. Comparative analysis of salivary bacterial microbiome diversity in edentulous infants and their mothers or primary care givers using pyrosequencing. PLoS One. 2011; 6:e23503. [PubMed: 21853142]
16. Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486:207–214. [PubMed: 22699609]
17. Kolenbrander PE, Andersen RN, Blehert DS, Eglund PG, Foster JS, Palmer RJ. Communication among Oral Bacteria. Microbiol Mol Biol Rev. 2002; 66:486–505. [PubMed: 12209001]

18. Palmer RJ Jr, Gordon SM, Cisar JO, Kolenbrander PE. Coaggregation-mediated interactions of streptococci and actinomyces detected in initial human dental plaque. *J Bacteriol.* 2003; 185:3400–3409. [PubMed: 12754239]
19. Nobbs AH, Lamont RJ, Jenkinson HF. *Streptococcus* adherence and colonization. *Microbiol Mol Biol Rev.* 2009; 73:407–450. [PubMed: 19721085]
20. Levine MJ, Herzberg MC, Levine MS, Ellison SA, Stinson MW, Li HC, van Dyke T. Specificity of salivary-bacterial interactions: role of terminal sialic acid residues in the interaction of salivary glycoproteins with *Streptococcus sanguis* and *Streptococcus mutans*. *Infect Immun.* 1978; 19:107–115. [PubMed: 415001]
21. McBride BC, Gisslow MT. Role of sialic acid in saliva-induced aggregation of *Streptococcus sanguis*. *Infect Immun.* 1977; 18:35–40. [PubMed: 908621]
22. Murray PA, Levine MJ, Reddy MS, Tabak LA, Bergey EJ. Preparation of a sialic acid-binding protein from *Streptococcus mitis* KS32AR. *Infect Immun.* 1986; 53:359–365. [PubMed: 3733221]
23. Murray PA, Levine MJ, Tabak LA, Reddy MS. Specificity of salivary-bacterial interactions: II. Evidence for a lectin on *Streptococcus sanguis* with specificity for a NeuAc alpha 2, 3Gal beta 1, 3GalNAc sequence. *Biochem Biophys Res Commun.* 1982; 106:390–396. [PubMed: 7104000]
24. Ellen RP, Fillery ED, Chan KH, Grove DA. Sialidase-enhanced lectin-like mechanism for *Actinomyces viscosus* and *Actinomyces naeslundii* hemagglutination. *Infect Immun.* 1980; 27:335–343. [PubMed: 6769798]
25. Gibbons RJ, Hay DI, Childs WC 3rd, Davis G. Role of cryptic receptors (cryptitopes) in bacterial adhesion to oral surfaces. *Arch Oral Biol.* 1990; 35(Suppl):107S–114S. [PubMed: 2088213]
26. Loimaranta V, Jakubovics NS, Hytonen J, Finne J, Jenkinson HF, Stromberg N. Fluid- or surface-phase human salivary scavenger protein gp340 exposes different bacterial recognition properties. *Infect Immun.* 2005; 73:2245–2252. [PubMed: 15784568]
27. Jakubovics NS, Kerrigan SW, Nobbs AH, Stromberg N, van Dolleweerd CJ, Cox DM, Kelly CG, Jenkinson HF. Functions of cell surface-anchored antigen I/II family and Hsa polypeptides in interactions of *Streptococcus gordonii* with host receptors. *Infect Immun.* 2005; 73:6629–6638. [PubMed: 16177339]
28. Jenkinson HF, Lamont RJ. Streptococcal adhesion and colonization. *Crit Rev Oral Biol Med.* 1997; 8:175–200. [PubMed: 9167092]
29. Busscher HJ, van de Belt-Gritter B, Dijkstra RJ, Norde W, Petersen FC, Scheie AA, HC vdM. Intermolecular forces and enthalpies in the adhesion of *Streptococcus mutans* and an antigen I/II-deficient mutant to laminin films. *J Bacteriol.* 2007; 189
30. Love RM, McMillan MD, Jenkinson HF. Invasion of dentinal tubules by oral streptococci is associated with collagen recognition mediated by the antigen I/II family of polypeptides. *Infect Immun.* 1997; 65:5157–5164. [PubMed: 9393810]
31. Kolenbrander PE, Palmer RJ Jr, Periasamy S, Jakubovics NS. Oral multispecies biofilm development and the key role of cell-cell distance. *Nat Rev Microbiol.* 2010; 8:471–480. [PubMed: 20514044]
32. Gibbons RJ, Nygaard M. Interbacterial aggregation of plaque bacteria. *Arch Oral Biol.* 1970; 15:1397–1400. [PubMed: 5280139]
33. Cisar JO, Kolenbrander PE, McIntire FC. Specificity of coaggregation reactions between human oral streptococci and strains of *Actinomyces viscosus* or *Actinomyces naeslundii*. *Infect Immun.* 1979; 24:742–752. [PubMed: 468376]
34. Kolenbrander PE, Andersen RN, Holdeman LV. Coaggregation of oral Bacteroides species with other bacteria: central role in coaggregation bridges and competitions. *Infect Immun.* 1985; 48:741–746. [PubMed: 3888842]
35. Kolenbrander PE, Andersen RN, Moore LV. Coaggregation of *Fusobacterium nucleatum*, *Selenomonas flueggei*, *Selenomonas infelix*, *Selenomonas noxia*, and *Selenomonas sputigena* with strains from 11 genera of oral bacteria. *Infect Immun.* 1989; 57:3194–3203. [PubMed: 2777378]
36. Jenkinson HF, Lala HC, Shepherd MG. Coaggregation of *Streptococcus sanguis* and other streptococci with *Candida albicans*. *Infect Immun.* 1990; 58:1429–1436. [PubMed: 2182544]
37. Listgarten MA. Structure of the microbial flora associated with periodontal health and disease in man. A light and electron microscopic study. *J Periodontol.* 1976; 47:1–18. [PubMed: 1063849]

38. Ozok AR, Persoon IF, Huse SM, Keijser BJ, Wesselink PR, Crielaard W, Zaura E. Ecology of the microbiome of the infected root canal system: a comparison between apical and coronal root segments. *Int Endod J*. 2012; 45:530–541. [PubMed: 22251411]
39. Bradshaw DJ, Homer KA, Marsh PD, Beighton D. Metabolic cooperation in oral microbial communities during growth on mucin. *Microbiology*. 1994; 140(Pt 12):3407–3412. [PubMed: 7881558]
40. Kuramitsu HK, He X, Lux R, Anderson MH, Shi W. Interspecies interactions within oral microbial communities. *Microbiol Mol Biol Rev*. 2007; 71:653–670. [PubMed: 18063722]
41. Grenier D, Mayrand D. Nutritional relationships between oral bacteria. *Infect Immun*. 1986; 53:616–620. [PubMed: 2875029]
42. Grenier D. Nutritional interactions between two suspected periodontopathogens, *Treponema denticola* and *Porphyromonas gingivalis*. *Infect Immun*. 1992; 60:5298–5301. [PubMed: 1333450]
43. Chikindas ML, Novak J, Driessen AJ, Konings WN, Schilling KM, Caufield PW. Mutacin II, a bactericidal antibiotic from *Streptococcus mutans*. *Antimicrob Agents Chemother*. 1995; 39:2656–2660. [PubMed: 8592997]
44. Donoghue HD, Tyler JE. Antagonisms amongst streptococci isolated from the human oral cavity. *Arch Oral Biol*. 1975; 20:381–387. [PubMed: 1057390]
45. Grenier D. Antagonistic effect of oral bacteria towards *Treponema denticola*. *J Clin Microbiol*. 1996; 34:1249–1252. [PubMed: 8727911]
46. Kaewsrichan J, Douglas CW, Nissen-Meyer J, Fimland G, Teanpaisan R. Characterization of a bacteriocin produced by *Prevotella nigrescens* ATCC 25261. *Lett Appl Microbiol*. 2004; 39:451–458. [PubMed: 15482437]
47. Kretz J, Merritt J, Shi W, Qi F. Competition and coexistence between *Streptococcus mutans* and *Streptococcus sanguinis* in the dental biofilm. *J Bacteriol*. 2005; 187:7193–7203. [PubMed: 16237003]
48. Liu X, Ramsey MM, Chen X, Koley D, Whiteley M, Bard AJ. Real-time mapping of a hydrogen peroxide concentration profile across a polymicrobial bacterial biofilm using scanning electrochemical microscopy. *Proc Natl Acad Sci U S A*. 2011; 108:2668–2673. [PubMed: 21282623]
49. Greer A, Zenobia C, Darveau RP. Defensins and LL-37: a review of function in the gingival epithelium. *Periodontol* 2000. 2013; 63:67–79. [PubMed: 23931055]
50. Huynh AH, Veith PD, McGregor NR, Adams GG, Chen D, Reynolds EC, Ngo LH, Darby IB. Gingival crevicular fluid proteomes in health, gingivitis and chronic periodontitis. *J Periodontal Res*. 2015; 50:637–649. [PubMed: 25439677]
51. van 't Hof W, Veerman EC, Nieuw Amerongen AV, Ligtenberg AJ. Antimicrobial defense systems in saliva. *Monogr Oral Sci*. 2014; 24:40–51. [PubMed: 24862593]
52. Marsh PD, Do T, Beighton D, Devine DA. Influence of saliva on the oral microbiota. *Periodontol* 2000. 2016; 70:80–92. [PubMed: 26662484]
53. Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, Tack BF, McCray PB Jr. Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. *Infect Immun*. 1999; 67:2740–2745. [PubMed: 10338476]
54. Blankenvoorde MF, van't Hof W, Walgreen-Weterings E, van Steenberghe TJ, Brand HS, Veerman EC, Nieuw Amerongen AV. Cystatin and cystatin-derived peptides have antibacterial activity against the pathogen *Porphyromonas gingivalis*. *Biol Chem*. 1998; 379:1371–1375. [PubMed: 9865612]
55. den Hertog AL, van Marle J, van Veen HA, Van't Hof W, Bolscher JG, Veerman EC, Nieuw Amerongen AV. Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. *Biochem J*. 2005; 388:689–695. [PubMed: 15707390]
56. MacKay BJ, Denepitiya L, Iacono VJ, Krost SB, Pollock JJ. Growth-inhibitory and bactericidal effects of human parotid salivary histidine-rich polypeptides on *Streptococcus mutans*. *Infect Immun*. 1984; 44:695–701. [PubMed: 6724693]

57. Pollock JJ, Denepitiya L, MacKay BJ, Iacono VJ. Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on *Candida albicans*. *Infect Immun*. 1984; 44:702–707. [PubMed: 6373615]
58. Hajishengallis G, Abe T, Maekawa T, Hajishengallis E, Lambris JD. Role of complement in host-microbe homeostasis of the periodontium. *Semin Immunol*. 2013; 25:65–72. [PubMed: 23684627]
59. Carpenter GH. The secretion, components, and properties of saliva. *Annu Rev Food Sci Technol*. 2013; 4:267–276. [PubMed: 23464573]
60. Ngo LH, Veith PD, Chen YY, Chen D, Darby IB, Reynolds EC. Mass spectrometric analyses of peptides and proteins in human gingival crevicular fluid. *J Proteome Res*. 2010; 9:1683–1693. [PubMed: 20020772]
61. ter Steeg PF, van der Hoeven JS, de Jong MH, van Munster PJJ, Jansen MJH. Modelling the gingival pocket by enrichment of subgingival microflora in human serum in chemostats. *Microb Ecol Health Dis*. 1988; 1:73–84.
62. ter Steeg PF, van der Hoeven JS, JAJM B. Immunoglobulin G Cleaving Species in Serum-degrading Consortia of Periodontal Bacteria. *Microb Ecol Health Dis*. 1989; 2:163–169.
63. Glenister DA, Salamon KE, Smith K, Beighton D, Keevil CW. Enhanced growth of complex communities of dental plaque bacteria in mucin-limited continuous culture. *Microb Ecol Health Dis*. 1988; 1:31–38.
64. ter Steeg PF, Van der Hoeven JS, de Jong MH, van Munster PJ, Jansen MJ. Enrichment of subgingival microflora on human serum leading to accumulation of *Bacteroides* species, *Peptostreptococci* and *Fusobacteria*. *Antonie Van Leeuwenhoek*. 1987; 53:261–272. [PubMed: 3674857]
65. Grenier D, Imbeault S, Plamondon P, Grenier G, Nakayama K, Mayrand D. Role of gingipains in growth of *Porphyromonas gingivalis* in the presence of human serum albumin. *Infect Immun*. 2001; 69:5166–5172. [PubMed: 11447200]
66. Grenier D, Mayrand D, McBride BC. Further studies on the degradation of immunoglobulins by black-pigmented *Bacteroides*. *Oral Microbiol Immunol*. 1989; 4:12–18. [PubMed: 2628862]
67. Bradshaw DJ, Marsh PD. Analysis of pH-driven disruption of oral microbial communities in vitro. *Caries Res*. 1998; 32:452–462.
68. Bradshaw DJ, McKee AS, Marsh PD. Effects of carbohydrate pulses and pH on population shifts within oral microbial communities in vitro. *J Dent Res*. 1989; 68:1298–1302. [PubMed: 2674233]
69. Gibbons RJ, Houte JV. Bacterial adherence in oral microbial ecology. *Annu Rev Microbiol*. 1975; 29:19–44. [PubMed: 1180512]
70. Mettraux GR, Gusberti FA, Graf H. Oxygen tension (pO₂) in untreated human periodontal pockets. *J Periodontol*. 1984; 55:516–521. [PubMed: 6592325]
71. Kenney EB, Ash MM Jr. Oxidation reduction potential of developing plaque, periodontal pockets and gingival sulci. *J Periodontol*. 1969; 40:630–633. [PubMed: 5260618]
72. Mager DL, Ximenez-Fyvie LA, Haffajee AD, Socransky SS. Distribution of selected bacterial species on intraoral surfaces. *J Clin Periodontol*. 2003; 30:644–654. [PubMed: 12834503]
73. Selwitz RH, Ismail AI, Pitts NB. Dental caries. *The Lancet*. 2007; 369:51–59.
74. Fontana M, Young DA, Wolff MS, Pitts NB, Longbottom C. Defining dental caries for 2010 and beyond. *Dent Clin North Am*. 2010; 54:423–440. [PubMed: 20630187]
75. van Houte J. Role of micro-organisms in caries etiology. *J Dent Res*. 1994; 73:672–681. [PubMed: 8163737]
76. Marsh PD. Are dental diseases examples of ecological catastrophes? *Microbiology*. 2003; 149:279–294. [PubMed: 12624191]
77. Becker MR, Paster BJ, Leys EJ, Moeschberger ML, Kenyon SG, Galvin JL, Boches SK, Dewhirst FE, Griffen AL. Molecular Analysis of Bacterial Species Associated with Childhood Caries. *J Clin Microbiol*. 2002; 40:1001–1009. [PubMed: 11880430]
78. Loesche WJ, Rowan J, Straffon LH, Loos PJ. Association of *Streptococcus mutants* with human dental decay. *Infect Immun*. 1975; 11:1252–1260. [PubMed: 1140847]
79. Marchant S, Brailsford SR, Twomey AC, Roberts GJ, Beighton D. The predominant microflora of nursing caries lesions. *Caries Res*. 2001; 35:397–406. [PubMed: 11799279]

80. Aas JA, Griffen AL, Dardis SR, Lee AM, Olsen I, Dewhirst FE, Leys EJ, Paster BJ. Bacteria of dental caries in primary and permanent teeth in children and young adults. *J Clin Microbiol.* 2008; 46:1407–1417. [PubMed: 18216213]
81. Belda-Ferre P, Alcaraz LD, Cabrera-Rubio R, Romero H, Simon-Soro A, Pignatelli M, Mira A. The oral metagenome in health and disease. *ISME J.* 2012; 6:46–56. [PubMed: 21716308]
82. Kanasi E, Dewhirst FE, Chalmers NI, Kent R Jr, Moore A, Hughes CV, Pradhan N, Loo CY, Tanner AC. Clonal analysis of the microbiota of severe early childhood caries. *Caries Res.* 2010; 44:485–497. [PubMed: 20861633]
83. Loesche WJ, Eklund S, Earnest R, Burt B. Longitudinal investigation of bacteriology of human fissure decay: epidemiological studies in molars shortly after eruption. *Infect Immun.* 1984; 46:765–772. [PubMed: 6500709]
84. Munson MA, Banerjee A, Watson TF, Wade WG. Molecular analysis of the microflora associated with dental caries. *J Clin Microbiol.* 2004; 42:3023–3029. [PubMed: 15243054]
85. Preza D, Olsen I, Aas JA, Willumsen T, Grinde B, Paster BJ. Bacterial profiles of root caries in elderly patients. *J Clin Microbiol.* 2008; 46:2015–2021. [PubMed: 18385433]
86. Tanner AC, Kent RL Jr, Holgerson PL, Hughes CV, Loo CY, Kanasi E, Chalmers NI, Johansson I. Microbiota of severe early childhood caries before and after therapy. *J Dent Res.* 2011; 90:1298–1305. [PubMed: 21868693]
87. van Ruyven FO, Lingstrom P, van Houte J, Kent R. Relationship among mutans streptococci, “low-pH” bacteria, and iodophilic polysaccharide-producing bacteria in dental plaque and early enamel caries in humans. *J Dent Res.* 2000; 79:778–784. [PubMed: 10728980]
88. Lamont RJ, Hajishengallis G. Polymicrobial synergy and dysbiosis in inflammatory disease. *Trends Mol Med.* 2015; 21:172–183. [PubMed: 25498392]
89. Armitage GC, Cullinan MP. Comparison of the clinical features of chronic and aggressive periodontitis. *Periodontol 2000.* 2010; 53:12–27. [PubMed: 20403102]
90. Lang N, Bartold PM, Cullinan M, Jeffcoat M, Mombelli A, Murakami S, Page R, Papapanou P, Tonetti M, Van Dyke T. Consensus report: aggressive periodontitis. *Annals Periodontol.* 1999; 4
91. Diaz PI, Hoare A, Hong BY. Subgingival microbiome shifts and community dynamics in periodontal diseases. *J Calif Dent Assoc.* 2016; 44:421–435. [PubMed: 27514154]
92. Kistler JO, Booth V, Bradshaw DJ, Wade WG. Bacterial community development in experimental gingivitis. *PLoS One.* 2013; 8:e71227. [PubMed: 23967169]
93. Huang S, Li R, Zeng X, He T, Zhao H, Chang A, Bo C, Chen J, Yang F, Knight R, Liu J, Davis C, Xu J. Predictive modeling of gingivitis severity and susceptibility via oral microbiota. *ISME J.* 2014; 8:1768–1780. [PubMed: 24646694]
94. Loe H, Theilade E, Jensen SB. Experimental Gingivitis in Man. *J Periodontol.* 1965; 36:177–187. [PubMed: 14296927]
95. Griffen AL, Beall CJ, Campbell JH, Firestone ND, Kumar PS, Yang ZK, Podar M, Leys EJ. Distinct and complex bacterial profiles in human periodontitis and health revealed by 16S pyrosequencing. *ISME J.* 2012; 6:1176–1185. [PubMed: 22170420]
96. Hong BY, Furtado Araujo MV, Strausbaugh LD, Terzi E, Ioannidou E, Diaz PI. Microbiome profiles in periodontitis in relation to host and disease characteristics. *PLoS One.* 2015; 10:e0127077. [PubMed: 25984952]
97. Kirst ME, Li EC, Alfant B, Chi YY, Walker C, Magnusson I, Wang GP. Dysbiosis and alterations in predicted functions of the subgingival microbiome in chronic periodontitis. *Appl Environ Microbiol.* 2015; 81:783–793. [PubMed: 25398868]
98. Fine DH, Kaplan JB, Kachlany SC, Schreiner HC. How we got attached to *Actinobacillus actinomycetemcomitans*: A model for infectious diseases. *Periodontol 2000.* 2006; 42:114–157. [PubMed: 16930309]
99. Kamma JJ, Nakou M, Gmur R, Baehni PC. Microbiological profile of early onset/aggressive periodontitis patients. *Oral Microbiol Immunol.* 2004; 19:314–321. [PubMed: 15327644]
100. Lourenco TG, Heller D, Silva-Boghossian CM, Cotton SL, Paster BJ, Colombo AP. Microbial signature profiles of periodontally healthy and diseased patients. *J Clin Periodontol.* 2014; 41:1027–1036. [PubMed: 25139407]

101. Oliveira RR, Fermiano D, Feres M, Figueiredo LC, Teles FR, Soares GM, Faveri M. Levels of Candidate Periodontal Pathogens in Subgingival Biofilm. *J Dent Res.* 2016; 95:711–718. [PubMed: 26936213]
102. Haubek D, Ennibi OK, Poulsen K, Vaeth M, Poulsen S, Kilian M. Risk of aggressive periodontitis in adolescent carriers of the JP2 clone of *Aggregatibacter (Actinobacillus) actinomycetemcomitans* in Morocco: a prospective longitudinal cohort study. *Lancet.* 2008; 371:237–242. [PubMed: 18207019]
103. Hajishengallis G, Lamont RJ. Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. *Mol Oral Microbiol.* 2012; 27:409–419. [PubMed: 23134607]
104. Jauregui CE, Wang Q, Wright CJ, Takeuchi H, Uriarte SM, Lamont RJ. Suppression of T-cell chemokines by *Porphyromonas gingivalis*. *Infect Immun.* 2013; 81:2288–2295. [PubMed: 23589576]
105. Takeuchi H, Hirano T, Whitmore SE, Morisaki I, Amano A, Lamont RJ. The serine phosphatase SerB of *Porphyromonas gingivalis* suppresses IL-8 production by dephosphorylation of NF-kappaB RelA/p65. *PLoS Pathog.* 2013; 9:e1003326. [PubMed: 23637609]
106. Popadiak K, Potempa J, Riesbeck K, Blom AM. Biphasic effect of gingipains from *Porphyromonas gingivalis* on the human complement system. *J Immunol.* 2007; 178:7242–7250. [PubMed: 17513773]
107. Jusko M, Potempa J, Karim AY, Ksiazek M, Riesbeck K, Garred P, Eick S, Blom AM. A metalloproteinase karilysin present in the majority of *Tannerella forsythia* isolates inhibits all pathways of the complement system. *J Immunol.* 2012; 188:2338–2349. [PubMed: 22287711]
108. Potempa M, Potempa J, Kantyka T, Nguyen KA, Wawrzonek K, Manandhar SP, Popadiak K, Riesbeck K, Eick S, Blom AM. Interpain A, a cysteine proteinase from *Prevotella intermedia*, inhibits complement by degrading complement factor C3. *PLoS Pathog.* 2009; 5:e1000316. [PubMed: 19247445]
109. Maekawa T, Krauss JL, Abe T, Jotwani R, Triantafilou M, Triantafilou K, Hashim A, Hoch S, Curtis MA, Nussbaum G, Lambris JD, Hajishengallis G. *Porphyromonas gingivalis* manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. *Cell Host Microbe.* 2014; 15:768–778. [PubMed: 24922578]
110. Maekawa T, Abe T, Hajishengallis E, Hosur KB, DeAngelis RA, Ricklin D, Lambris JD, Hajishengallis G. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. *J Immunol.* 2014; 192:6020–6027. [PubMed: 24808362]
111. Lalla RV, Patton LL, Dongari-Bagtzoglou A. Oral candidiasis: pathogenesis, clinical presentation, diagnosis and treatment strategies. *J Calif Dent Assoc.* 2013; 41:263–268. [PubMed: 23705242]
112. Williams D, Lewis M. Pathogenesis and treatment of oral candidosis. *J Oral Microbiol.* 2011; 3
113. Muadcheingka T, Tantivitayakul P. Distribution of *Candida albicans* and non-*albicans* *Candida* species in oral candidiasis patients: Correlation between cell surface hydrophobicity and biofilm forming activities. *Arch Oral Biol.* 2015; 60:894–901. [PubMed: 25819801]
114. Salvatori O, Puri S, Tati S, Edgerton M. Innate Immunity and Saliva in *Candida albicans*-mediated Oral Diseases. *J Dent Res.* 2016; 95:365–371. [PubMed: 26747422]
115. Diaz PI, Xie Z, Sobue T, Thompson A, Biyikoglu B, Ricker A, Ikonomou L, Dongari-Bagtzoglou A. Synergistic interaction between *Candida albicans* and commensal oral streptococci in a novel in vitro mucosal model. *Infect Immun.* 2012; 80:620–632. [PubMed: 22104105]
116. Xu H, Sobue T, Thompson A, Xie Z, Poon K, Ricker A, Cervantes J, Diaz PI, Dongari-Bagtzoglou A. Streptococcal co-infection augments *Candida* pathogenicity by amplifying the mucosal inflammatory response. *Cell Microbiol.* 2014; 16:214–231. [PubMed: 24079976]
117. Bamford CV, d'Mello A, Nobbs AH, Dutton LC, Vickerman MM, Jenkinson HF. *Streptococcus gordonii* modulates *Candida albicans* biofilm formation through intergeneric communication. *Infect Immun.* 2009; 77:3696–3704. [PubMed: 19528215]
118. FAO/WHO J. Report of a Joint FAO/WHO expert consultation on guidelines for the evaluation of probiotics in food. World Health Organization and Food and Agriculture Organization of the United Nations; Ontario, Canada: 2002.

119. Bron PA, van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. *Nat Rev Microbiol.* 2012; 10:66–78.
120. Lebeer S, Vanderleyden J, De Keersmaecker SC. Genes and molecules of lactobacilli supporting probiotic action. *Microbiol Mol Biol Rev.* 2008; 72:728–764. Table of Contents. [PubMed: 19052326]
121. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. *Gastroenterology.* 2007; 132:562–575. [PubMed: 17258729]
122. Gao C, Major A, Rendon D, Lugo M, Jackson V, Shi Z, Mori-Akiyama Y, Versalovic J. Histamine H2 Receptor-Mediated Suppression of Intestinal Inflammation by Probiotic *Lactobacillus reuteri*. *MBio.* 2015; 6:e01358–01315. [PubMed: 26670383]
123. Li J, Sung CY, Lee N, Ni Y, Pihlajamäki J, Panagiotou G, El-Nezami H. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. *Proc Natl Acad Sci U S A.* 2016; 113:E1306–1315. [PubMed: 26884164]
124. Everard A, Matamoros S, Geurts L, Delzenne NM, Cani PD. *Saccharomyces boulardii* administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. *MBio.* 2014; 5:e01011–01014. [PubMed: 24917595]
125. Jahn HU, Ullrich R, Schneider T, Liehr RM, Schieferdecker HL, Holst H, Zeitz M. Immunological and trophical effects of *Saccharomyces boulardii* on the small intestine in healthy human volunteers. *Digestion.* 1996; 57:95–104. [PubMed: 8786007]
126. Martins FS, Vieira AT, Elian SD, Arantes RM, Tiago FC, Sousa LP, Araujo HR, Pimenta PF, Bonjardim CA, Nicoli JR, Teixeira MM. Inhibition of tissue inflammation and bacterial translocation as one of the protective mechanisms of *Saccharomyces boulardii* against *Salmonella* infection in mice. *Microbes Infect.* 2013; 15:270–279. [PubMed: 23376166]
127. Justino PF, Melo LF, Nogueira AF, Costa JV, Silva LM, Santos CM, Mendes WO, Costa MR, Franco AX, Lima AA, Ribeiro RA, Souza MH, Soares PM. Treatment with *Saccharomyces boulardii* reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice. *Br J Nutr.* 2014; 111:1611–1621. [PubMed: 24503021]
128. Fanning S, Hall LJ, Cronin M, Zomer A, MacSharry J, Goulding D, Motherway MO, Shanahan F, Nally K, Dougan G, van Sinderen D. Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. *Proc Natl Acad Sci U S A.* 2012; 109:2108–2113. [PubMed: 22308390]
129. Asahara T, Shimizu K, Nomoto K, Hamabata T, Ozawa A, Takeda Y. Probiotic Bifidobacteria Protect Mice from Lethal Infection with Shiga Toxin-Producing *Escherichia coli* O157:H7. *Infect Immun.* 2004; 72:2240–2247. [PubMed: 15039348]
130. Klaenhammer TR. Bacteriocins of lactic acid bacteria. *Biochimie.* 1988; 70:337–349. [PubMed: 3139051]
131. Lee YK, Lim CY, Teng WL, Ouwehand AC, Tuomola EM, Salminen S. Quantitative approach in the study of adhesion of lactic acid bacteria to intestinal cells and their competition with enterobacteria. *Appl Environ Microbiol.* 2000; 66:3692–3697. [PubMed: 10966378]
132. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of *Lactobacillus* strains to intestinal epithelial cells in vitro. *Gut.* 2003; 52:827–833. [PubMed: 12740338]
133. McNulty NP, Yatsunenko T, Hsiao A, Faith JJ, Muegge BD, Goodman AL, Henrissat B, Oozeer R, Cools-Portier S, Gobert G, Chervaux C, Knights D, Lozupone CA, Knight R, Duncan AE, Bain JR, Muehlbauer MJ, Newgard CB, Heath AC, Gordon JI. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. *Sci Transl Med.* 2011; 3:106ra106.
134. Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, Flint HJ, Dieleman LA, Ringel Y, Guandalini S, Kelly CP, Brandt LJ. Recommendations for probiotic use-2011 update. *J Clin Gastroenterol.* 2011; 45:S168–171. [PubMed: 21992958]
135. Floch MH. Recommendations for probiotic use in humans-a 2014 update. *Pharmaceuticals (Basel).* 2014; 7:999–1007. [PubMed: 25310351]

136. Floch MH, Walker WA, Sanders ME, Nieuwdorp M, Kim AS, Brenner DA, Qamar AA, Miloh TA, Guarino A, Guslandi M, Dieleman LA, Ringel Y, Quigley EM, Brandt LJ. Recommendations for Probiotic Use—2015 Update: Proceedings and Consensus Opinion. *J Clin Gastroenterol*. 2015; 49(Suppl 1):S69–73. [PubMed: 26447969]
137. Allaker RP, Douglas CW. Novel anti-microbial therapies for dental plaque-related diseases. *Int J Antimicrob Agents*. 2009; 33:8–13. [PubMed: 18804350]
138. Tagg JR, Dierksen KP. Bacterial replacement therapy: adapting ‘germ warfare’ to infection prevention. *Trends Biotechnol*. 2003; 21:217–223. [PubMed: 12727383]
139. Hillman JD, Brooks TA, Michalek SM, Harmon CC, Snoep JL, van Der Weijden CC. Construction and characterization of an effector strain of *Streptococcus mutans* for replacement therapy of dental caries. *Infect Immun*. 2000; 68:543–549. [PubMed: 10639415]
140. Tanzer JM, Fisher J, Freedman ML. Preemption of *Streptococcus mutans* 10449S colonization by its mutant 805. *Infect Immun*. 1982; 35:138–142. [PubMed: 6459292]
141. Roos K, Hakansson EG, Holm S. Effect of recolonisation with “interfering” alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. *BMJ*. 2001; 322:210–212. [PubMed: 11159619]
142. Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. *Science*. 2016; 352:535–538. [PubMed: 27126035]
143. Petrof EO, Claud EC, Gloor GB, Allen-Vercoe E. Microbial ecosystems therapeutics: a new paradigm in medicine? *Benef Microbes*. 2013; 4:53–65. [PubMed: 23257018]
144. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med*. 2013; 368:407–415. [PubMed: 23323867]
145. Shahinas D, Silverman M, Sittler T, Chiu C, Kim P, Allen-Vercoe E, Weese S, Wong A, Low DE, Pillai DR. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. *MBio*. 2012; 3:e00338–00312. [PubMed: 23093385]
146. Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, Logan RM, Nair RG, Stringer AM, Yazbeck R, Elad S, Lalla RV, Mucositis Study Group of Multinational Association of Supportive Care in Cancer/International Society of Oral O. Emerging evidence on the pathobiology of mucositis. *Support Care Cancer*. 2013; 21:2075–2083. [PubMed: 23604521]
147. Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. *J Clin Gastroenterol*. 2003; 37:42–47. [PubMed: 12811208]
148. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. *Gastroenterology*. 2015; 149:102–109 e106. [PubMed: 25857665]
149. Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. *Am J Gastroenterol*. 2014; 109:1831–1832.
150. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroe ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology*. 2012; 143:913–916 e7. [PubMed: 22728514]
151. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, Kim S, Fritz JV, Wilmes P, Ueha S, Matsushima K, Ohno H, Olle B, Sakaguchi S, Taniguchi T, Morita H, Hattori M, Honda K. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. *Nature*. 2013; 500:232–236. [PubMed: 23842501]
152. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG. Precision microbiome reconstitution restores bile acid mediated resistance to *Clostridium difficile*. *Nature*. 2015; 517:205–208. [PubMed: 25337874]

153. Martin MO. Predatory prokaryotes: an emerging research opportunity. *J Mol Microbiol Biotechnol.* 2002; 4:467–477. [PubMed: 12432957]
154. Sockett RE, Lambert C. *Bdellovibrio* as therapeutic agents: a predatory renaissance? *Nat Rev Microbiol.* 2004; 2:669–675. [PubMed: 15263901]
155. Dwidar M, Monnappa AK, Mitchell RJ. The dual probiotic and antibiotic nature of *Bdellovibrio bacteriovorus*. *BMB Rep.* 2012; 45:71–78. [PubMed: 22360883]
156. Markelova NY. Interaction of *Bdellovibrio bacteriovorus* with bacteria *Campylobacter jejuni* and *Helicobacter pylori*. *Microbiology.* 2010; 79:777–779.
157. Shanks RM, Davra VR, Romanowski EG, Brothers KM, Stella NA, Godbole D, Kadouri DE. An Eye to a Kill: Using Predatory Bacteria to Control Gram-Negative Pathogens Associated with Ocular Infections. *PLoS One.* 2013; 8:e66723. [PubMed: 23824756]
158. Dashiff A, Kadouri DE. Predation of oral pathogens by *Bdellovibrio bacteriovorus* 109J. *Mol Oral Microbiol.* 2011; 26:19–34. [PubMed: 21214870]
159. Van Essche M, Quirynen M, Sliepen I, Loozen G, Boon N, Van Eldere J, Teughels W. Killing of anaerobic pathogens by predatory bacteria. *Mol Oral Microbiol.* 2011; 26:52–61. [PubMed: 21214872]
160. Atterbury RJ, Hobley L, Till R, Lambert C, Capeness MJ, Lerner TR, Fenton AK, Barrow P, Sockett RE. Effects of orally administered *Bdellovibrio bacteriovorus* on the well-being and *Salmonella* colonization of young chicks. *Appl Environ Microbiol.* 2011; 77:5794–5803. [PubMed: 21705523]
161. Guttman, B., Raya, R., Kutter, E. Basic phage biology. In: Kutter, E S Ae, editor. *Bacteriophages: biology and application.* CRC Press, LLC; Boca Raton, FL, USA: 2005. p. 29–66.
162. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. *Bacteriophage.* 2011; 1:66–85. [PubMed: 22334863]
163. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. Bacteriophage cocktail for the prevention of biofilm formation by *Pseudomonas aeruginosa* on catheters in an in vitro model system. *Antimicrob Agents Chemother.* 2010; 54:397–404. [PubMed: 19822702]
164. Hall AR, De Vos D, Friman VP, Pirnay JP, Buckling A. Effects of sequential and simultaneous applications of bacteriophages on populations of *Pseudomonas aeruginosa* in vitro and in wax moth larvae. *Appl Environ Microbiol.* 2012; 78:5646–5652. [PubMed: 22660719]
165. Torres-Barcelo C, Arias-Sanchez FI, Vasse M, Ramsayer J, Kaltz O, Hochberg ME. A window of opportunity to control the bacterial pathogen *Pseudomonas aeruginosa* combining antibiotics and phages. *PLoS One.* 2014; 9:e106628. [PubMed: 25259735]
166. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant *Pseudomonas aeruginosa*; a preliminary report of efficacy. *Clin Otolaryngol.* 2009; 34:349–357. [PubMed: 19673983]
167. Rose T, Verbeken G, Vos DD, Merabishvili M, Vaneechoutte M, Lavigne R, Jennes S, Zizi M, Pirnay JP. Experimental phage therapy of burn wound infection: difficult first steps. *Int J Burns Trauma.* 2014; 4:66–73. [PubMed: 25356373]
168. Armitage GC, Robertson PB. The Biology, Prevention, Diagnosis and Treatment of Periodontal Diseases. *J Am Dent Assoc.* 2009; 140:36S–43S. [PubMed: 19723929]
169. Weyant RJ, Tracy SL, Anselmo TT, Beltran-Aguilar ED, Donly KJ, Frese WA, Hujoel PP, Iafolla T, Kohn W, Kumar J, Levy SM, Tinanoff N, Wright JT, Zero D, Aravamudhan K, Frantsve-Hawley J, Meyer DM, American Dental Association Council on Scientific Affairs Expert Panel on Topical Fluoride Caries Preventive A. Topical fluoride for caries prevention: executive summary of the updated clinical recommendations and supporting systematic review. *J Am Dent Assoc.* 2013; 144:1279–1291. [PubMed: 24177407]
170. Sharma G, Puranik MP, K RS. Approaches to Arresting Dental Caries: An Update. *J Clin Diagn Res.* 2015; 9:ZE08–11. [PubMed: 26155592]
171. Haffajee AD, Uzel NG, Arguello EI, Torresyap G, Guerrero DM, Socransky SS. Clinical and microbiological changes associated with the use of combined antimicrobial therapies to treat “refractory” periodontitis. *J Clin Periodontol.* 2004; 31:869–877. [PubMed: 15367191]

172. Bizzarro S, Laine ML, Buijs MJ, Brandt BW, Crielaard W, Loos BG, Zaura E. Microbial profiles at baseline and not the use of antibiotics determine the clinical outcome of the treatment of chronic periodontitis. *Sci Rep*. 2016; 6:20205. [PubMed: 26830979]
173. Ford CB, Funt JM, Abbey D, Issi L, Guiducci C, Martinez DA, Delorey T, Li BY, White TC, Cuomo C, Rao RP, Berman J, Thompson DA, Regev A. The evolution of drug resistance in clinical isolates of *Candida albicans*. *Elife*. 2015; 4:e00662. [PubMed: 25646566]
174. Kalantar E, Marashi SM, Pormazaheri H, Mahmoudi E, Hatami S, Barari MA, Naseh MH, Asadi M. First experience of *Candida non-albicans* isolates with high antibiotic resistance pattern caused oropharyngeal candidiasis among cancer patients. *J Cancer Res Ther*. 2015; 11:388–390. [PubMed: 26148605]
175. Tanzer JM, Kurasz AB, Clive J. Competitive displacement of mutans streptococci and inhibition of tooth decay by *Streptococcus salivarius* TOVE-R. *Infect Immun*. 1985; 48:44–50. [PubMed: 3980093]
176. Hillman JD. Lactate dehydrogenase mutants of *Streptococcus mutans*: isolation and preliminary characterization. *Infect Immun*. 1978; 21:206–212. [PubMed: 30695]
177. Hillman JD, Dzback AL, Andrews SW. Colonization of the human oral cavity by a *Streptococcus mutans* mutant producing increased bacteriocin. *J Dent Res*. 1987; 66:1092–1094. [PubMed: 3476580]
178. Hillman JD, Mo J, McDonell E, Cvitkovitch D, Hillman CH. Modification of an effector strain for replacement therapy of dental caries to enable clinical safety trials. *J Appl Microbiol*. 2007; 102:1209–1219. [PubMed: 17448156]
179. Tanzer JM, Kurasz AB, Clive J. Inhibition of ecological emergence of mutans streptococci naturally transmitted between rats and consequent caries inhibition by *Streptococcus salivarius* TOVE-R infection. *Infect Immun*. 1985; 49:76–83. [PubMed: 4008050]
180. Kurasz AB, Tanzer JM, Bazer L, Savoldi E. In vitro studies of growth and competition between *S. salivarius* TOVE-R and mutans streptococci. *J Dent Res*. 1986; 65:1149–1153. [PubMed: 3461031]
181. Hillman JD, Johnson KP, Yaphe BI. Isolation of a *Streptococcus mutans* strain producing a novel bacteriocin. *Infect Immun*. 1984; 44:141–144. [PubMed: 6706403]
182. Hillman JD, Yaphe BI, Johnson KP. Colonization of the human oral cavity by a strain of *Streptococcus mutans*. *J Dent Res*. 1985; 64:1272–1274. [PubMed: 3912416]
183. Stensson M, Koch G, Coric S, Abrahamsson TR, Jenmalm MC, Birkhed D, Wendt LK. Oral administration of *Lactobacillus reuteri* during the first year of life reduces caries prevalence in the primary dentition at 9 years of age. *Caries Res*. 2014; 48:111–117. [PubMed: 24296746]
184. Ahola AJ, Yli-Knuuttila H, Suomalainen T, Poussa T, Ahlstrom A, Meurman JH, Korpela R. Short-term consumption of probiotic-containing cheese and its effect on dental caries risk factors. *Arch Oral Biol*. 2002; 47:799–804. [PubMed: 12446187]
185. Bhalla M, Ingle NA, Kaur N, Yadav P. Mutans streptococci estimation in saliva before and after consumption of probiotic curd among school children. *J Int Soc Prev Community Dent*. 2015; 5:31–34. [PubMed: 25767764]
186. Caglar E, Sandalli N, Twetman S, Kavaloglu S, Ergeneli S, Selvi S. Effect of yogurt with *Bifidobacterium* DN-173 010 on salivary mutans streptococci and lactobacilli in young adults. *Acta Odontol Scand*. 2005; 63:317–320. [PubMed: 16512103]
187. Caglar E, Cildir SK, Ergeneli S, Sandalli N, Twetman S. Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium *Lactobacillus reuteri* ATCC 55730 by straws or tablets. *Acta Odontol Scand*. 2006; 64:314–318. [PubMed: 16945898]
188. Caglar E, Kavaloglu SC, Kuscu OO, Sandalli N, Holgerson PL, Twetman S. Effect of chewing gums containing xylitol or probiotic bacteria on salivary mutans streptococci and lactobacilli. *Clin Oral Investig*. 2007; 11:425–429.
189. Caglar E, Kuscu OO, Selvi Kuvvetli S, Kavaloglu Cildir S, Sandalli N, Twetman S. Short-term effect of ice-cream containing *Bifidobacterium lactis* Bb-12 on the number of salivary mutans streptococci and lactobacilli. *Acta Odontol Scand*. 2008; 66:154–158. [PubMed: 18568474]

190. Campus G, Cocco F, Carta G, Cagetti MG, Simark-Mattson C, Strohmenger L, Lingstrom P. Effect of a daily dose of *Lactobacillus brevis* CD2 lozenges in high caries risk schoolchildren. Clin Oral Investig. 2014; 18:555–561.
191. Chuang LC, Huang CS, Ou-Yang LW, Lin SY. Probiotic *Lactobacillus paracasei* effect on cariogenic bacterial flora. Clin Oral Investig. 2011; 15:471–476.
192. Cildir SK, Germec D, Sandalli N, Ozdemir FI, Arun T, Twetman S, Caglar E. Reduction of salivary mutans streptococci in orthodontic patients during daily consumption of yoghurt containing probiotic bacteria. Eur J Orthod. 2009; 31:407–411. [PubMed: 19193706]
193. Jindal G, Pandey RK, Agarwal J, Singh M. A comparative evaluation of probiotics on salivary mutans streptococci counts in Indian children. Eur Arch Paediatr Dent. 2011; 12:211–215. [PubMed: 21806906]
194. Juneja A, Kakade A. Evaluating the effect of probiotic containing milk on salivary mutans streptococci levels. J Clin Pediatr Dent. 2012; 37:9–14. [PubMed: 23342560]
195. Nikawa H, Makihira S, Fukushima H, Nishimura H, Ozaki Y, Ishida K, Darmawan S, Hamada T, Hara K, Matsumoto A, Takemoto T, Aimi R. *Lactobacillus reuteri* in bovine milk fermented decreases the oral carriage of mutans streptococci. Int J Food Microbiol. 2004; 95:219–223. [PubMed: 15282133]
196. Singh RP, Damle SG, Chawla A. Salivary mutans streptococci and lactobacilli modulations in young children on consumption of probiotic ice-cream containing *Bifidobacterium lactis* Bb12 and *Lactobacillus acidophilus* La5. Acta Odontol Scand. 2011; 69:389–394. [PubMed: 21466258]
197. Srivastava S, Saha S, Kumari M, Mohd S. Effect of Probiotic Curd on Salivary pH and *Streptococcus mutans*: A Double Blind Parallel Randomized Controlled Trial. J Clin Diagn Res. 2016; 10:ZC13–16.
198. Teanpaisan R, Piwat S. *Lactobacillus paracasei* SD1, a novel probiotic, reduces mutans streptococci in human volunteers: a randomized placebo-controlled trial. Clin Oral Investig. 2014; 18:857–862.
199. Nishihara T, Suzuki N, Yoneda M, Hirofujii T. Effects of *Lactobacillus salivarius*-containing tablets on caries risk factors: a randomized open-label clinical trial. BMC Oral Health. 2014; 14:110. [PubMed: 25178882]
200. Aminabadi NA, Erfanparast L, Ebrahimi A, Oskouei SG. Effect of chlorhexidine pretreatment on the stability of salivary lactobacilli probiotic in six- to twelve-year-old children: a randomized controlled trial. Caries Res. 2011; 45:148–154. [PubMed: 21454978]
201. Keller MK, Twetman S. Acid production in dental plaque after exposure to probiotic bacteria. BMC Oral Health. 2012; 12:44. [PubMed: 23092239]
202. Marttinen A, Haukioja A, Karjalainen S, Nylund L, Satokari R, Ohman C, Holgersson P, Twetman S, Soderling E. Short-term consumption of probiotic lactobacilli has no effect on acid production of supragingival plaque. Clin Oral Investig. 2012; 16:797–803.
203. Nozari A, Motamedifar M, Seifi N, Hatamizargaran Z, Ranjbar MA. The Effect of Iranian Customary Used Probiotic Yogurt on the Children's Salivary Cariogenic Microflora. J Dent (Shiraz). 2015; 16:81–86. [PubMed: 26046102]
204. Pinto GS, Cenci MS, Azevedo MS, Epifanio M, Jones MH. Effect of yogurt containing *Bifidobacterium animalis* subsp. *lactis* DN-173010 probiotic on dental plaque and saliva in orthodontic patients. Caries Res. 2014; 48:63–68. [PubMed: 24217196]
205. Rodriguez G, Ruiz B, Faleiros S, Vistoso A, Marro ML, Sanchez J, Urzua I, Cabello R. Probiotic Compared with Standard Milk for High-caries Children: A Cluster Randomized Trial. J Dent Res. 2016; 95:402–407. [PubMed: 26747421]
206. Nase L, Hatakka K, Savilahti E, Saxelin M, Ponka A, Poussa T, Korpela R, Meurman JH. Effect of long-term consumption of a probiotic bacterium, *Lactobacillus rhamnosus* GG, in milk on dental caries and caries risk in children. Caries Res. 2001; 35:412–420. [PubMed: 11799281]
207. Hasslof P, West CE, Videhult FK, Brandelius C, Stecksén-Blicks C. Early intervention with probiotic *Lactobacillus paracasei* F19 has no long-term effect on caries experience. Caries Res. 2013; 47:559–565. [PubMed: 23838478]

208. Taipale T, Pienihakkinen K, Alanen P, Jokela J, Soderling E. Administration of *Bifidobacterium animalis* subsp. *lactis* BB-12 in early childhood: a post-trial effect on caries occurrence at four years of age. *Caries Res.* 2013; 47:364–372. [PubMed: 23571819]
209. Bosch M, Nart J, Audivert S, Bonachera MA, Alemany AS, Fuentes MC, Cune J. Isolation and characterization of probiotic strains for improving oral health. *Arch Oral Biol.* 2012; 57:539–549. [PubMed: 22054727]
210. Terai T, Okumura T, Imai S, Nakao M, Yamaji K, Ito M, Nagata T, Kaneko K, Miyazaki K, Okada A, Nomura Y, Hanada N. Screening of Probiotic Candidates in Human Oral Bacteria for the Prevention of Dental Disease. *PLoS One.* 2015; 10:e0128657. [PubMed: 26053410]
211. Burton JP, Drummond BK, Chilcott CN, Tagg JR, Thomson WM, Hale JD, Wescombe PA. Influence of the probiotic *Streptococcus salivarius* strain M18 on indices of dental health in children: a randomized double-blind, placebo-controlled trial. *J Med Microbiol.* 2013; 62:875–884. [PubMed: 23449874]
212. Zahradnik RT, Magnusson I, Walker C, McDonell E, Hillman CH, Hillman JD. Preliminary assessment of safety and effectiveness in humans of ProBiora3, a probiotic mouthwash. *J Appl Microbiol.* 2009; 107:682–690. [PubMed: 19486429]
213. Gruner D, Paris S, Schwendicke F. Probiotics for managing caries and periodontitis: Systematic review and meta-analysis. *J Dent.* 2016; 48:16–25. [PubMed: 26965080]
214. Nascimento MM, Liu Y, Kalra R, Perry S, Adewumi A, Xu X, Primosch RE, Burne RA. Oral arginine metabolism may decrease the risk for dental caries in children. *J Dent Res.* 2013; 92:604–608. [PubMed: 23640952]
215. do Nascimento C, Ferreira de Albuquerque R Junior, Issa JP, Ito IY, Lovato da Silva CH, de Freitas Oliveira Paranhos H, de Souza RF. Use of the DNA Checkerboard hybridization method for detection and quantitation of *Candida* species in oral microbiota. *Can J Microbiol.* 2009; 55:622–626. [PubMed: 19483792]
216. Huang X, Schulte RM, Burne RA, Nascimento MM. Characterization of the arginolytic microflora provides insights into pH homeostasis in human oral biofilms. *Caries Res.* 2015; 49:165–176. [PubMed: 25634570]
217. Huang X, Palmer SR, Ahn SJ, Richards VP, Williams ML, Nascimento MM, Burne RA. A Highly Arginolytic *Streptococcus* Species That Potently Antagonizes *Streptococcus mutans*. *Appl Environ Microbiol.* 2016; 82:2187–2201. [PubMed: 26826230]
218. Nascimento MM, Browngardt C, Xiaohui X, Klepac-Ceraj V, Paster BJ, Burne RA. The effect of arginine on oral biofilm communities. *Mol Oral Microbiol.* 2014; 29:45–54. [PubMed: 24289808]
219. Roberts FA, Darveau RP. Beneficial bacteria of the periodontium. *Periodontol 2000.* 2002; 30:40–50. [PubMed: 12236894]
220. Teughels W, Loozen G, Quirynen M. Do probiotics offer opportunities to manipulate the periodontal oral microbiota? *J Clin Periodontol.* 2011; 38(Suppl 11):159–177. [PubMed: 21323712]
221. Cosseau C, Devine DA, Dullaghan E, Gardy JL, Chikatarla A, Gellatly S, Yu LL, Pistolic J, Falsafi R, Tagg J, Hancock RE. The commensal *Streptococcus salivarius* K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. *Infect Immun.* 2008; 76:4163–4175. [PubMed: 18625732]
222. Zhang G, Chen R, Rudney JD. *Streptococcus cristatus* attenuates *Fusobacterium nucleatum*-induced interleukin-8 expression in oral epithelial cells. *Journal of Periodontal Research.* 2008; 43:408–416. [PubMed: 18942189]
223. Zhang G, Rudney JD. *Streptococcus cristatus* attenuates *Fusobacterium nucleatum*-induced cytokine expression by influencing pathways converging on nuclear factor-kappaB. *Mol Oral Microbiol.* 2011; 26:150–163. [PubMed: 21375705]
224. Riccia DN, Bizzini F, Perilli MG, Polimeni A, Trinchieri V, Amicosante G, Cifone MG. Anti-inflammatory effects of *Lactobacillus brevis* (CD2) on periodontal disease. *Oral Dis.* 2007; 13:376–385. [PubMed: 17577323]

225. Maekawa T, Hajishengallis G. Topical treatment with probiotic *Lactobacillus brevis* CD2 inhibits experimental periodontal inflammation and bone loss. *J Periodontol Res.* 2014; 49:785–791. [PubMed: 24483135]
226. Hillman JD, Shivers M. Interaction between wild-type, mutant and revertant forms of the bacterium *Streptococcus sanguis* and the bacterium *Actinobacillus actinomycetemcomitans* in vitro and in the gnotobiotic rat. *Arch Oral Biol.* 1988; 33:395–401. [PubMed: 3228385]
227. Sliepen I, Van Essche M, Loozen G, Van Eldere J, Quirynen M, Teughels W. Interference with *Aggregatibacter actinomycetemcomitans*: colonization of epithelial cells under hydrodynamic conditions. *Oral Microbiol Immunol.* 2009; 24:390–395. [PubMed: 19702952]
228. Teughels W, Kinder Haake S, Sliepen I, Pauwels M, Van Eldere J, Cassiman JJ, Quirynen M. Bacteria interfere with *A. actinomycetemcomitans* colonization. *J Dent Res.* 2007; 86:611–617. [PubMed: 17586706]
229. Van Hoogmoed CG, Geertsema-Doornbusch GI, Teughels W, Quirynen M, Busscher HJ, Van der Mei HC. Reduction of periodontal pathogens adhesion by antagonistic strains. *Oral Microbiol Immunol.* 2008; 23:43–48. [PubMed: 18173797]
230. Hojo K, Nagaoka S, Murata S, Taketomo N, Ohshima T, Maeda N. Reduction of vitamin K concentration by salivary *Bifidobacterium* strains and their possible nutritional competition with *Porphyromonas gingivalis*. *J Appl Microbiol.* 2007; 103:1969–1974. [PubMed: 17953607]
231. Vicario M, Santos A, Violant D, Nart J, Giner L. Clinical changes in periodontal subjects with the probiotic *Lactobacillus reuteri* Prodentis: a preliminary randomized clinical trial. *Acta Odontol Scand.* 2013; 71:813–819. [PubMed: 23176716]
232. Vivekananda MR, Vandana KL, Bhat KG. Effect of the probiotic *Lactobacilli reuteri* (Prodentis) in the management of periodontal disease: a preliminary randomized clinical trial. *J Oral Microbiol.* 2010; 2:10. 3402/jom.v3402i3400.5344.
233. Morales A, Carvajal P, Silva N, Hernandez M, Godoy C, Rodriguez G, Cabello R, Garcia-Sesnich J, Hoare A, Diaz PI, Gamonal J. Clinical Effects of *Lactobacillus Rhamnosus* in Non-Surgical Treatment of Chronic Periodontitis: A Randomized Placebo-Controlled Trial With 1-Year Follow-up. *J Periodontol.* 2016; 87:944–952. [PubMed: 26944407]
234. Teughels W, Durukan A, Ozcelik O, Pauwels M, Quirynen M, Haytac MC. Clinical and microbiological effects of *Lactobacillus reuteri* probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study. *J Clin Periodontol.* 2013; 40:1025–1035. [PubMed: 24164569]
235. Laleman I, Yilmaz E, Ozcelik O, Haytac C, Pauwels M, Herrero ER, Slomka V, Quirynen M, Alkaya B, Teughels W. The effect of a streptococci containing probiotic in periodontal therapy: a randomized controlled trial. *J Clin Periodontol.* 2015; 42:1032–1041. [PubMed: 26427036]
236. Krasse P, Carlsson B, Dahl C, Paulsson A, Nilsson A, Sinkiewicz G. Decreased gum bleeding and reduced gingivitis by the probiotic *Lactobacillus reuteri*. *Swed Dent J.* 2006; 30:55–60. [PubMed: 16878680]
237. Twetman S, Derawi B, Keller M, Ekstrand K, Yucel-Lindberg T, Steckslen-Blicks C. Short-term effect of chewing gums containing probiotic *Lactobacillus reuteri* on the levels of inflammatory mediators in gingival crevicular fluid. *Acta Odontol Scand.* 2009; 67:19–24. [PubMed: 18985460]
238. Slawik S, Staufienbiel I, Schilke R, Nicksch S, Weinspach K, Stiesch M, Eberhard J. Probiotics affect the clinical inflammatory parameters of experimental gingivitis in humans. *Eur J Clin Nutr.* 2011; 65:857–863. [PubMed: 21448219]
239. Iniesta M, Herrera D, Montero E, Zurbruggen M, Matos AR, Marin MJ, Sanchez-Beltran MC, Llama-Palacio A, Sanz M. Probiotic effects of orally administered *Lactobacillus reuteri*-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial. *J Clin Periodontol.* 2012; 39:736–744. [PubMed: 22694350]
240. Karuppaiah RM, Shankar S, Raj SK, Ramesh K, Prakash R, Kruthika M. Evaluation of the efficacy of probiotics in plaque reduction and gingival health maintenance among school children – A Randomized Control Trial. *J Int Oral Health.* 2013; 5:33–37. [PubMed: 24324302]
241. Mayanagi G, Kimura M, Nakaya S, Hirata H, Sakamoto M, Benno Y, Shimauchi H. Probiotic effects of orally administered *Lactobacillus salivarius* WB21-containing tablets on

- periodontopathic bacteria: a double-blinded, placebo-controlled, randomized clinical trial. *J Clin Periodontol.* 2009; 36:506–513. [PubMed: 19453574]
242. Staab B, Eick S, Knofler G, Jentsch H. The influence of a probiotic milk drink on the development of gingivitis: a pilot study. *J Clin Periodontol.* 2009; 36:850–856. [PubMed: 19682173]
 243. Shimauchi H, Mayanagi G, Nakaya S, Minamibuchi M, Ito Y, Yamaki K, Hirata H. Improvement of periodontal condition by probiotics with *Lactobacillus salivarius* WB21: a randomized, double-blind, placebo-controlled study. *J Clin Periodontol.* 2008; 35:897–905. [PubMed: 18727656]
 244. Teughels W, Newman MG, Coucke W, Haffajee AD, Van Der Mei HC, Haake SK, Schepers E, Cassiman JJ, Van Eldere J, van Steenberghe D, Quirynen M. Guiding periodontal pocket recolonization: a proof of concept. *J Dent Res.* 2007; 86:1078–1082. [PubMed: 17959900]
 245. Nackaerts O, Jacobs R, Quirynen M, Rober M, Sun Y, Teughels W. Replacement therapy for periodontitis: pilot radiographic evaluation in a dog model. *J Clin Periodontol.* 2008; 35:1048–1052. [PubMed: 19040581]
 246. Dewhirst FE, Klein EA, Thompson EC, Blanton JM, Chen T, Milella L, Buckley CM, Davis IJ, Bennett ML, Marshall-Jones ZV. The canine oral microbiome. *PLoS One.* 2012; 7:e36067. [PubMed: 22558330]
 247. Sturgeon A, Stull JW, Costa MC, Weese JS. Metagenomic analysis of the canine oral cavity as revealed by high-throughput pyrosequencing of the 16S rRNA gene. *Vet Microbiol.* 2013; 162:891–898. [PubMed: 23228621]
 248. Pozhitkov AE, Leroux BG, Randolph TW, Beikler T, Flemmig TF, Noble PA. Towards microbiome transplant as a therapy for periodontitis: an exploratory study of periodontitis microbial signature contrasted by oral health, caries and edentulism. *BMC Oral Health.* 2015; 15:125. [PubMed: 26468081]
 249. Van Essche M, Quirynen M, Sliepen I, Van Eldere J, Teughels W. *Bdellovibrio bacteriovorus* attacks *Aggregatibacter actinomycetemcomitans*. *J Dent Res.* 2009; 88:182–186. [PubMed: 19278992]
 250. Loozen G, Boon N, Pauwels M, Slomka V, Rodrigues Herrero E, Quirynen M, Teughels W. Effect of *Bdellovibrio bacteriovorus* HD100 on multispecies oral communities. *Anaerobe.* 2015; 35:45–53. [PubMed: 25252124]
 251. Schoeffield AJ, Williams HN, Turng B, Fackler WA Jr. A Comparison of the Survival of Intraperiplasmic and Attack Phase *Bdellovibrios* with Reduced Oxygen. *Microb Ecol.* 1996; 32:35–46. [PubMed: 8661540]
 252. Abeles SR, Pride DT. Molecular bases and role of viruses in the human microbiome. *J Mol Biol.* 2014; 426:3892–3906. [PubMed: 25020228]
 253. Edlund A, Santiago-Rodriguez TM, Boehm TK, Pride DT. Bacteriophage and their potential roles in the human oral cavity. *J Oral Microbiol.* 2015; 7:27423. [PubMed: 25861745]
 254. Pride DT, Salzman J, Haynes M, Rohwer F, Davis-Long C, White RA 3rd, Loomer P, Armitage GC, Relman DA. Evidence of a robust resident bacteriophage population revealed through analysis of the human salivary virome. *ISME J.* 2012; 6:915–926. [PubMed: 22158393]
 255. Hitch G, Pratten J, Taylor PW. Isolation of bacteriophages from the oral cavity. *Lett Appl Microbiol.* 2004; 39:215–219. [PubMed: 15242464]
 256. Ly M, Abeles SR, Boehm TK, Robles-Sikisaka R, Naidu M, Santiago-Rodriguez T, Pride DT. Altered oral viral ecology in association with periodontal disease. *MBio.* 2014; 5:e01133–01114. [PubMed: 24846382]
 257. Machuca P, Daille L, Vines E, Berrocal L, Bittner M. Isolation of a novel bacteriophage specific for the periodontal pathogen *Fusobacterium nucleatum*. *Appl Environ Microbiol.* 2010; 76:7243–7250. [PubMed: 20851973]
 258. Castillo-Ruiz M, Vines ED, Montt C, Fernandez J, Delgado JM, Hormazabal JC, Bittner M. Isolation of a novel *Aggregatibacter actinomycetemcomitans* serotype b bacteriophage capable of lysing bacteria within a biofilm. *Appl Environ Microbiol.* 2011; 77:3157–3159. [PubMed: 21378052]

259. Ishijima SA, Hayama K, Burton JP, Reid G, Okada M, Matsushita Y, Abe S. Effect of *Streptococcus salivarius* K12 on the in vitro growth of *Candida albicans* and its protective effect in an oral candidiasis model. *Appl Environ Microbiol.* 2012; 78:2190–2199. [PubMed: 22267663]
260. Matsubara VH, Wang Y, Bandara HM, Mayer MP, Samaranayake LP. Probiotic lactobacilli inhibit early stages of *Candida albicans* biofilm development by reducing their growth, cell adhesion, and filamentation. *Appl Microbiol Biotechnol.* 2016; 100:6415–6426. [PubMed: 27087525]
261. James KM, MacDonald KW, Chanyi RM, Cadieux PA, Burton JP. Inhibition of *Candida albicans* biofilm formation and modulation of gene expression by probiotic cells and supernatant. *J Med Microbiol.* 2016; 65:328–336. [PubMed: 26847045]
262. Vilela SF, Barbosa JO, Rossoni RD, Santos JD, Prata MC, Anbinder AL, Jorge AO, Junqueira JC. *Lactobacillus acidophilus* ATCC 4356 inhibits biofilm formation by *C. albicans* and attenuates the experimental candidiasis in *Galleria mellonella*. *Virulence.* 2015; 6:29–39. [PubMed: 25654408]
263. Zhao C, Lv X, Fu J, He C, Hua H, Yan Z. In vitro inhibitory activity of probiotic products against oral *Candida* species. *J Appl Microbiol.* 2016; 121:254–262. [PubMed: 26999745]
264. Matsubara VH, Silva EG, Paula CR, Ishikawa KH, Nakamae AE. Treatment with probiotics in experimental oral colonization by *Candida albicans* in murine model (DBA/2). *Oral Dis.* 2012; 18:260–264. [PubMed: 22059932]
265. Elahi S, Pang G, Ashman R, Clancy R. Enhanced clearance of *Candida albicans* from the oral cavities of mice following oral administration of *Lactobacillus acidophilus*. *Clin Exp Immunol.* 2005; 141:29–36. [PubMed: 15958067]
266. Ishijima SA, Hayama K, Ninomiya K, Iwasa M, Yamazaki M, Abe S. Protection of mice from oral Candidiasis by heat-killed *Enterococcus faecalis*, possibly through its direct binding to *Candida albicans*. *Med Mycol J.* 2014; 55:E9–E19. [PubMed: 24682096]
267. Hatakka K, Ahola AJ, Yli-Knuuttila H, Richardson M, Poussa T, Meurman JH, Korpela R. Probiotics reduce the prevalence of oral *Candida* in the elderly—a randomized controlled trial. *J Dent Res.* 2007; 86:125–130. [PubMed: 17251510]
268. Kraft-Bodi E, Jorgensen MR, Keller MK, Kragelund C, Twetman S. Effect of Probiotic Bacteria on Oral *Candida* in Frail Elderly. *J Dent Res.* 2015; 94:181S–186S. [PubMed: 26202995]
269. Mendonca FH, Santos SS, Faria Ida S, Goncalves e Silva CR, Jorge AO, Leao MV. Effects of probiotic bacteria on *Candida* presence and IgA anti-*Candida* in the oral cavity of elderly. *Braz Dent J.* 2012; 23:534–538. [PubMed: 23306230]
270. Li D, Li Q, Liu C, Lin M, Li X, Xiao X, Zhu Z, Gong Q, Zhou H. Efficacy and safety of probiotics in the treatment of *Candida*-associated stomatitis. *Mycoses.* 2014; 57:141–146. [PubMed: 23952962]
271. Ishikawa KH, Mayer MP, Miyazima TY, Matsubara VH, Silva EG, Paula CR, Campos TT, Nakamae AE. A multispecies probiotic reduces oral *Candida* colonization in denture wearers. *J Prosthodont.* 2015; 24:194–199. [PubMed: 25143068]
272. Xie H, Lin X, Wang BY, Wu J, Lamont RJ. Identification of a signalling molecule involved in bacterial intergeneric communication. *Microbiology.* 2007; 153:3228–3234. [PubMed: 17906122]
273. Christopher AB, Arndt A, Cugini C, Davey ME. A streptococcal effector protein that inhibits *Porphyromonas gingivalis* biofilm development. *Microbiology.* 2010; 156:3469–3477. [PubMed: 20705665]
274. Wang BY, Wu J, Lamont RJ, Lin X, Xie H. Negative correlation of distributions of *Streptococcus cristatus* and *Porphyromonas gingivalis* in subgingival plaque. *J Clin Microbiol.* 2009; 47:3902–3906. [PubMed: 19846640]
275. Borenstein E. Computational systems biology and in silico modeling of the human microbiome. *Brief Bioinform.* 2012; 13:769–780. [PubMed: 22589385]
276. Takahashi N. Oral Microbiome Metabolism: From “Who Are They?” to “What Are They Doing?”. *J Dent Res.* 2015; 94:1628–1637. [PubMed: 26377570]

277. Duran-Pinedo AE, Chen T, Teles R, Starr JR, Wang X, Krishnan K, Frias-Lopez J. Community-wide transcriptome of the oral microbiome in subjects with and without periodontitis. *ISME J.* 2014; 8:1659–1672. [PubMed: 24599074]
278. Jorth P, Turner KH, Gumus P, Nizam N, Buduneli N, Whiteley M. Metatranscriptomics of the human oral microbiome during health and disease. *MBio.* 2014; 5:e01012–01014. [PubMed: 24692635]
279. Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN, Van Dyke TE. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. *J Immunol.* 2007; 179:7021–7029. [PubMed: 17982093]

Figure 1.

Dysbiotic changes associated with oral diseases. Oral diseases are associated with changes in microbiome community structure. Examples of microbiome community shifts and the main factors promoting the establishment of the dysbiotic microbiota are depicted for caries, periodontal diseases and oral candidiasis.

Figure 2.

Potential beneficial effects of microbial therapies in the management of oral diseases. The desirable effects of the introduction of effector species/communities together with complementary therapies are shown for caries, periodontal diseases and oral candidiasis.